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ABSTRACT 
  
 A novel high flow rate cell capture design was introduced to overcome the 
limitations of the current technologies or methods for rare target cell capture. Even 
though the rare target cell capture using BioMEMS technology has great potential for 
cancer diagnosis, previous rare cell capture research could not overcome the 
limitations of low flow rate or low recovery rate. 
 Rare cell research requires precise sample preparation for accurate results. A new 
method of preparation for a single or a precise number of target cell was introduced. 
Current sample preparation methods which are not suitable for rare cell research, such 
as CTC capture or single cell analysis do not provide precise cell counts below 100. A 
cell collection chip was designed and used with a polyimide removed capillary tube 
to collect an exact number of target cells under a microscope.  
 To optimize the dimensions of the high flow rate design, CFD (Fluent v6.3, 
ANSYS, Inc., Canonsburg, PA, USA) simulation was used. The design focused on a 
high flow rate at inlet and low axial and lateral velocities in the cell capture regions 
with a small footprint. Based on the simulation results, the dimensions for several 
prototypes were determined and fabricated in PMMA. 
 The CTCs, MCF-7 cells, were captured flow rates up to 750 µL/min from 40% 
red blood cells with 80% recovery rate using the high flow rate device. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Human Breast Cancer 
 Human breast cancer is the leading cause of death from cancer for women in this century 
[1, 2]. More than 211,000 American women are told that they have this disease every year. 
Estimated new cases and deaths from breast cancer in the United States in 2010 were 
209,060 cases (207,090 for female and 1,970 for male) and 40,230 deaths (39,840 for female 
and 390 for male) [3]. Because of the continuing efforts to develop screening and diagnosis 
technology and the improvements in surgical and other treatment methods, survivors` 
lifetimes have increased and the mortality, the rate of deaths compared to the number of 
cases, decreased over the last few decades [3, 4]. However, breast cancer is still one of the 
most dangerous diseases leading to death and it is very hard to treat once it has metastasized 
to other organs in the patient`s body [2, 3, 5]. Figure 1.1 shows the incidence and mortality 
rates of breast cancer in the USA. 
1.1.1 Origins and Characteristics of Cancer in the Human Body 
 Normal cell growth occurs at times, to replace worn cells, to grow tissue during 
development, or to create new life during pregnancy. It is normally very well controlled. 
However, cells can sometimes grow improperly and multiple mutations can make normal 
cells into tumor cells [6-8]. Cancer cells are uncontrolled, malignant, immortal, and do not 
stop growing as long as sufficient nutrients are available from their environment. They may 
travel anywhere in the body via a single cell migration [9-11]. The origin of cancer is not yet 
clearly defined, but some basic causes of cancer are chemicals, radiation,  
2 
 
 
 
Figure 1.1 Incidence and mortality of breast cancer in United States [12] 
 
and viruses [13]. Tumors can be localized or metastasize to other organs. The invasion of 
tumor cells can start at the very beginning of tumor development [11, 14].  Moreover, the 
mechanism of metastasis is not well understood [10, 11]. 
1.1.2 Staging of Human Breast Cancer and Survival Rates 
 The stage at which breast cancer is detected significantly affects the survival rates [15]. 
The time course of breast cancer is divided into four stages. Alternatively, it can be 
subdivided as six stages based on the size, number of palpable lymph nodes, and metastasis 
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of the tumor [4, 16, 17]. A schematic diagram shown in Figure 1.2 indicates the locations of 
the axillaries and nodes. 
 Stage 0 is the condition of no primary tumor or carcinoma in situ. Stage 1 is early stage 
invasive breast cancer and the tumors are less than 2 cm in dimension and located only in the 
breast. Ten year relative survival rates for Stage 0 are 95% and for Stage 1 are 88%. Stage 2 
is subdivided into two sub-categories (Stage 2-A and Stage 2-B) based on tumor size and 
lymph node involvement. Stage 2-A has two cases. Either the size of the tumor is between 2 
cm and 5 cm and has not spread to the surrounding lymph nodes or the size of tumor is less 
than 2 cm but has spread to up to three axillary underarm lymph nodes. Stage 2-B also 
includes two cases. Either the size of the tumor is larger than 5 cm without spreading to the 
surrounding lymph nodes or the size of tumor is between 2 and 5 cm with spreading to up to 
three axillary underarm lymph nodes.  
 
 
1. Low axillary, Level 1 
2. Mid-axillary, Level 2 
3. High axillary, apical, Level 3 
4. Supraclavicular 
5. Internal mammary nodes 
Figure 1.2 Schematic diagram of the breast and regional lymph nodes [17] 
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Stage 3 is subdivided into two categories (Stage 3-A and Stage 3-B) based on the tumor 
size and lymph node involvement. If the size of tumor is less than 5 cm in diameter and 
spreads to four to nine underarm lymph nodes, it is stage 3-A. A tumor over 5 cm size 
involved with up to nine axillary nodes or to internal mammary nodes, it can be also stage 3-
A. Stage 3-B is reached when the tumor spreads through the chest wall or skin, to the ribs 
and muscles. During the last stage, Stage 4, the tumor spreads to other organs in the body 
such as the bones, lungs, liver, and brain. Ten year relative survival rates for Stage 2 are 66%, 
for Stage 3 36%, and for Stage 4 just 7% [15].  
1.1.3 Human Breast Cancer Treatment at Different Stages 
 The method of treatment of breast cancer can be guided by the stage of the breast cancer. 
The stage of breast cancer reflects the eventual mortality and is also directly related to the 
quality of life for the patient, because earlier detection requires easier, less invasive treatment. 
Figure 1.3 shows the relationship between survival rate and the stage of breast cancer [15].  
 For early stages, such as Stages 1 or 2, breast-sparing surgery, also called breast-
conserving surgery, and radiation therapy are commonly used as the primary treatment. 
Breast-sparing surgery is the removal of the breast cancer tissue, or the removal of a lump or 
part of the breast, but not the breast itself. At Stage 3, local treatment, including surgery and 
radiation therapy, and systemic treatment, comprised of chemotherapy or hormonal therapy, 
are needed to remove the cancer and to prevent additional spreading. Stage 4 breast cancer is 
commonly treated by chemotherapy and hormonal therapy with surgery followed by 
radiation, including other metastasized body parts. Therefore, early detection will allow the 
easier treatment, potentially a longer life time, and a better quality of life [5, 18]. 
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Figure 1.3 Relative survival rates of breast cancer patients combined cancer stage group from 
1985 to 1990 [15] 
 
1.2 Diagnosis of Human Breast Cancer 
1.2.1 Historical Review of Breast Cancer Detection 
 In the early 20
th
 century, X-ray imaging was suggested for detection of breast cancer as 
an initial breast cancer diagnosis. However, mammography did not begin to emerge as a 
clinical tool until the 1960s. Later, advances in technology led to the use of other 
technologies, such as ultrasound (US), magnetic resonance imaging (MRI), and optical 
imaging, as acceptable and recommendable diagnostic methods. Major improvements in the 
past 30 years include the reduction of radiation doses, automatic control of exposure, 
development of better imaging technology, digitizing of images, and computer-aided 
detection [4, 19]. 
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Figure 1.4 A history of breast cancer screening [4]. 
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1.2.2 Current Clinical Methods 
 Currently, screening and diagnosis of breast cancer can be done using various 
technologies such as Full Field Digital Mammography (FFDM), Computer-Aided Detection 
and Diagnosis (CAD), Ultrasound (US), Magnetic Resonance Imaging (MRI). Figure 1.5 is a 
picture of a commercial mammography machine for breast cancer detection. Routine 
screening using these techniques decreased the mortality of breast cancer to 25 ~ 30 percent 
among women 50 to 70 years old age [4]. However, the sensitivity of current breast cancer 
screening methods is not high enough. Clinical breast examination, mammography, and MRI 
detect 17.8%, 40%, and 71.7% of all breast cancers, respectively. For invasive breast cancer, 
the sensitivity of clinical breast examination is down to 17.9%, 33.3%, and 79.5% for 
mammography, and MRI, respectively [20]. The combination of these technologies with a  
 
Figure 1.5 Commercial mammography machine for breast cancer detection 
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biopsy is recommended to make up for the weak points in each technique, but is not perfect 
and does not address the need for early stage detection; Ultrasound can detect 40% of breast 
cancer and the combination of mammography and ultrasound can detect 49% [21]. 
Commercial technology can detect tumors with diameters of approximately 1 cm usually [18, 
22]. Mammography, ultrasound, and MRI can detect invasive tumors with mean sizes of 13.2 
mm, 15.1 mm, and 12.4 mm, respectively [21]. The resolution or detectable minimum size 
tumor also depends on the density of the breast, the location of the tumor, and other 
conditions. Due to the limitations of these commercial systems and methods, it is necessary 
to develop or find other ways to accomplish early detection and diagnosis. 
1.2.3 BioMEMS for Diagnosis 
 Micro Electro Mechanical System (MEMS) technology was developed as a new research 
field from microelectronics fabrication in the 1960`s and commercialization began in the 
1980`s. The applications of MEMS are varied and it has a great potential [23]. MEMS are 
commonly used as sensors, analyzers, or actuators in mechanical, electrical, optical, chemical, 
biological, and medical applications.  
 As a subset of MEMS, BioMEMS has specialized in the role of sensor, analyzer, and 
actuator for micro total analysis systems for biological, clinical, and biomedical applications 
[24-29]. One of the most promising BioMEMS uses is the field of diagnostics. In diagnostics, 
BioMEMS give a better option compared to commercial technology or products because of 
the small sample requirement, fast response time, low cost, disposability, and small footprint. 
Based on the these advantages, commercial products using BioMEMS technology are in the 
market including a portable blood tester, CTC detection, and capsule endoscopy (See the 
Figure 1.6.) 
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(a) (b) (c) 
Figure 1.6 Commercial diagnosis products of BioMEMS technology: (a) portable blood 
tester [30], (b) CellSearch System [31], and (c) capsule endoscopy [32] 
 
 Moreover, BioMEMS technology may be a solution to reach the requirement of the early 
stage human breast cancer diagnosis. Many researchers have demonstrated methods for early 
human breast cancer detection or separation [33-44]. Veridex, LLC launched a CellSearch 
system (Veridex, Raritan, NJ, USA) for circulating tumor detection. However, it has not 
reached the standard of performance necessary for point-of-care uses for human cancer 
diagnosis at an early stage. 
 
1.3 Motivation for This Project 
1.3.1 BioMEMS Approach for Breast Cancer Diagnosis 
 BioMEMS approaches have been introduced for tumor detection [34-37, 39-46]. One of 
the approaches for the early stage breast cancer diagnosis is the separation or capture of 
circulating tumor cells (CTCs) because it has great potential for easy routine screening and 
can potentially produce a diagnosis at an early stage. CTCs are present on the earliest stages 
of tumor development [11, 14]. Moreover, captured or separated CTCs may minimize the 
bio-noise or uncertainty of identification. Captured CTCs can be clearly confirmed or 
identified with a type of tumor, either a benign or malignant tumor or an epithelial non-tumor, 
http://www.veridex.com 
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by other subsequent analysis, such as PCR or LDR. So, it can be a direct test instead of 
mammography and biopsy. 
 The methods of target cell detection and separation using BioMEMS can be classified as 
gene analysis-based [47-50], optically-based [27, 51-53], size-based [29, 33, 42, 44, 45, 54-
58], or affinity-based [34-36, 43, 59, 60]. Even though BioMEMS have a great potential for 
diagnostics, human breast cancer diagnosis as a point-of-care application has not been 
realized due to the poor sensitivity, low detection rate, or low throughput. These limitations 
actually are due to the rarity of tumor cells in the blood particularly at the early stages. Most 
recently published accomplishments are from Nagrath, et al. 2007 [34], Stott, et al. 2010 [43], 
Wang, et al. 2011 [40], Feng, et al. 2003 [36], and Adams, et al. 2008 [35]. Nagrath showed 
the successful CTC capture from human whole blood using BioMEMS. However, the flow 
rate was too low, 1mL/hr to get a high recovery rate, and the recovery rate was less than 80%. 
Stott reported a 79% recovery rate with a flow rate of 1.2 mL/hr [43]. Wang achieved a 95% 
recovery rate but at 2 mL/hr. Adams obtained better results, a flow rate of 1.92 mL/hr to get a 
maximum recovery rate (97%), with multiple parallel sinusoidal channels using spiked rabbit 
blood. However, it would take 4 hours to evaluate a 7.5 mL sample; the required minimum 
sample volume of 7.5 mL is necessary to get acceptable accuracy and to define the survival 
rate [61]. Moreover, the initial number of target cells in sample preparations for most of these 
experiments could not be clearly verified because they were controlled and counted 
statistically. This uncertainty in sample preparation affects the evaluation of the results. 
Therefore, the technology is not fast enough and not yet suitable for clinical use. 
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1.4 Goals of This Research 
 A method of diagnosing human breast cancer at an early stage by taking advantage of 
BioMEMS technology could overcome the limitations of current commercial methods. This 
project can save more lives with an easy and economical method since BioMEMS 
technology has the potential to replace expensive and time consuming commercial breast 
cancer diagnostic methods. This new technology can economically replace the current 
methods of breast cancer diagnosis.  
 This research was focused on a new method to introduce a connection between 
BioMEMS technology and the clinic for diagnosis with a point-of-care concept. It will 
demonstrate a suitable design, method, and experimental confirmation to be used in a 
medical or clinical uses with fast results and high capture accuracy from precisely prepared 
target cell populations in large sample volumes using BioMEMS. Moreover, the target cells 
are not only breast cancer cells, but also any kind of circulating tumor cells with proper 
biomarkers such as colorectal cancer, breast cancer, lung cancer, ovarian cancer, or prostate 
cancer [62]. Therefore, the application of this method can be much broader and the impact 
can be high. By developing, polymer micro devices manufacturing cost can be minimized 
and a disposable diagnosis system realized. The point-of-care device can maximize access to 
cancer diagnosis. Easy and simple accessibility of cancer diagnosis (as a manner of time, cost, 
and location or portability) should eventually reduce the mortality of cancer.  
 The goal of this research was the development of a disposable polymer micro CTC 
capture device with a high flow rate, a high recovery rate, and a high purity without pre-
treatment of the sample. Moreover, the device should allow further molecular analysis to 
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minimize false-positive results and to obtain more specific and detailed information after 
target cell capture. 
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CHAPTER 2: BACKGROUND 
 
 
2.1 Introduction 
A basic background on human blood including physical/biological properties, immune 
systems, and blood rheology are given in this chapter since circulating tumors cells (CTCs) 
exist in the human peripheral blood. Biological or physical properties of blood cells can 
distinguish and identify the CTCs from blood cells. The immune system uses fundamental 
antigen/antibody reactions, which can be used for specific CTC capture. Blood rheology is 
very important for CTC capture or separation because it changes the blood properties, and 
affects the lateral location of CTCs in devices. Moreover, non-Newtonian blood flow is an 
important factor for microfluidic systems.  
Current technologies for CTC capture are summarized in this chapter. Six approaches 
have been used and the advantages and disadvantages of each are discussed. Commercial 
products are also reviewed. Based on the technology review, the goals of this research are 
explained. 
 
2.2 Peripheral Human Blood 
2.2.1 Physical Properties 
 Blood is a viscous fluid mixture of 55 % plasma and 45 % cells. The components of 
plasma are 92 % water and 8 % protein, metabolites and ions [1, 2]. The cells in blood can be 
divided into red blood cells (Erythrocytes), white blood cells (Leukocytes), and platelets 
(fragments of megakaryocytes). The density of the plasma and the cells is about 1,025 kg/m
3
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and 1,125 kg/m
3
 respectively. Red blood cells or erythrocytes comprise 95% of whole blood 
cells, 4 ~ 6   106 cells/µL. Red blood cells have a biconcave disk shape because the nucleus 
is squeezed out and ingested by the macrophage during creation in bone marrow. 
Erythrocytes can provide the optimal deformability with maximum surface area for gas 
exchange. The platelets compose around 4.9% of whole blood, 1.5 ~ 4   105 cells/µL. The 
white blood cells or leukocytes count as 0.1% of cellular components of blood, 4 ~ 11   103 
cells/µL (normally 1/700 number of red blood cells). The size and shapes of blood cells are 6 
~ 8 µm diameter with 1 ~ 3 µm thickness for normal red blood cells, 7 ~ 20 µm diameter 
with spherical shape white blood cells, and 2 ~ 5 µm platelets.  Table 2.1 shows the size and 
shape of the different blood cells. 
 Leukocytes can be separated into five different types in two groups based on the specific 
granularity or nucleus type [3]. The five different types of leukocytes are neutrophils, 
eosinophils, basophile, lymphocytes, and monocytes.  Neutrophils, eosinophils, and 
basophils are called granulocytes, granular leukocytes, or polymorphonuclear leukocytes due 
to the presence of granules in their cytoplasm. Lymphocytes, monocytes, macrophages, and 
dendritic cells are grouped as agranulocytes (agranular leukocyte) or mononuclear leukocytes.  
The proportion of each type of leukocyte are; neutrophils 50 ~ 75%; eosinophils 2 ~ 4%; 
basophils 0.5 ~ 1%; lymphocytes 20 ~ 40%; and monocytes 3 ~ 8%. The proportion depends  
Table 2.1 Sizes and shapes of blood cells 
Size and shape of blood cells Diameter [μm] Shape 
Red blood cells (Erythrocytes) 6 ~ 8 (Thickness: 1 ~ 3) Biconcave disk 
White blood cells (Leukocytes) 7 ~ 20 Spherical 
Platelets 2 ~ 5 Fragments 
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on the gender, age, and condition of the body. The numbers of leukocytes can be increased 
by disease. The size of each type of leukocyte is 7 ~ 9 µm for neutrophils, 9 ~ 10 µm for 
eosinophils, 7 ~ 9 µm for basophils, 7 ~ 9 µm for lymphocytes, and 9 ~ 12 µm for monocytes. 
The size of leukocytes based on the type is summarized in Table 2.2.  
The normal pH of whole blood is 7.35 ~ 7.4 and viscosity is 3.0 cP at 37 °C. However, 
the viscosity depends on the hematocrit, the ratio of red blood cells to whole blood, and the 
velocity of the blood flow. Figure 2.1 shows a scanning electron microscope (SEM) image of 
human blood. 
Table 2.2 Size of leukocytes 
Leukocyte types Size [μm] 
Neutrophil 7 ~ 9 
Eosinophil 9 ~ 10 
Basophil 7 ~ 9 
Lymphocyte 7 ~ 9 
Monocyte 9 ~ 12 
 
 
Figure 2.1 Circulating blood cells, erythrocytes, leukocytes, and platelets, in a human body [4] 
  
http://visualsonline.cancer.gov 
Platelets 
Erythrocytes 
Leukocytes 
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2.2.2 Biological Properties and Functions 
 Human blood has two main functions, transportation and defense. Transport is done by 
red blood cells and plasma. Defense is carried out by white blood cells and serum [5]. Red 
blood cells transport oxygen and carbon dioxide through the body.  One red blood cell can 
contain three hundred thousand molecules of hemoglobin. Since a single hemoglobin can 
carry four molecules of oxygen, one red blood cell can transport 1.2 million molecules of 
oxygen. Plasma delivers or removes various ions (Na
+
, Ca2
+
, HCO3
-
, etc), glucose, amino 
acids, other organic acids, cholesterol and other lipids, hormones, urea and other wastes. 
White blood cells protect the body from infection or any other foreign materials. Platelets 
stop bleeding by solidification of the blood, known as coagulation or clotting. 
 The blood also maintains the pH in the rage 6.8 to 7.4 to avoid cell damage and maintains 
the body temperature; a pH below 6.8 or a pH above 7.8 will cause serious damage.  Human 
blood cells are derived from hematopoietic stem cells in the bone marrow.  Figure 2.2 shows 
the development of blood cells from a blood stem cell. A healthy adult produces more than 
10
12
 hematopoietic cells to produce any necessary blood cells every day. 
 
Figure 2.2 Development of human blood cells from a human blood stem cell in the bone 
marrow [4] 
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2.3 The Immune System in the Human Body 
 The immune system can protect bodies from bacteria, viruses, and parasites, which have 
never been encountered before. The body can produce over 10
8
 distinct antibodies and more 
than 10
12
 T-cell receptors with very specific distinguishable abilities [6]. The immune system 
has two parallel but interconnected systems, the humoral and cellular immune responses.  
 The humoral immune response works by antigen-antibody reactions. An antibody, 
immunoglobulin, functions as a recognition element that binds to foreign molecules and 
signals foreign invasion. The antibody is secreted by plasma cells which are originally 
derived from B cells. The antigen is any foreign macromolecule which has a specific affinity 
for an antibody. Thus, each antigen binds selectively to a specific antibody. Therefore, the 
humoral immune response, antigen/antibody reaction is not a whole macromolecular event, 
but an event at a particular site on the antigen.  
 The cellular immune response is primarily driven by cytotoxic T lymphocytes, called 
killer T cells, which kill cells displaying foreign motifs on their surface. Helper T 
lymphocytes stimulate the differentiation and proliferation of appropriate B cells and 
cytotoxic T cells, contributing to both the humoral and the cellular immune responses. 
Specific receptors that are expressed on the surface of the T cells mediate the cellular 
immune response. Originally, all of the cells of the immune system are derived from the 
hematopoietic stem cell and differentiated from one type of stem cell, shown in Figure 2.2. 
Despite the immune system, tumors are capable of evading immune recognition [7].   
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2.3.1 Lymphocytes and the Immune Response  
 Three types of lymphocytes, which are differentiated from hematopoietic stem cells, play 
a major role in the immune system: B cells, T cells, and natural killer cells. In the peripheral 
blood, B cells are 10-20% of lymphocytes, T cells account for 70-75%, and natural killer 
cells (NK cells) comprise 10-15%. Most of the lymphoid cells in the peripheral lymphoid 
tissues are B cells lineage [3, 6, 8].  
 B cells or B-lymphocytes, which are developed in the bone marrow, produce antibodies 
and memorize the signal of antigen to reproduce. When contacting an antigen, B-cells 
differentiate into the plasma to secrete antibodies or into B-memory cells. B cells need to 
cooperate with T-cells for an efficient antibody response and immune defense. 
 T cells or T-lymphocytes, which are developed in the thymus, differentiate into two 
classes: CD4-positive T-lymphocytes (CD4
+
 or helper T cells) and CD8-positive T-
lymphocytes (CD8
+
, cytotoxic, killer, or suppressor T-cells). Helper T cells recognize foreign 
antigens, stimulate B cells to produce antibodies, and contribute to the development of killer 
T cells. Killer T cells react with foreign antigens, take cell-mediated immune response, and 
control the proliferation of other T-cell subsets. Figure 2.3 shows the immune response of T 
lymphocytes by the process of antigen presentation by macrophages. 
 Natural killer cells do not need to recognize a specific antigen (natural immunity) and are 
capable of killing some tumor cells. However, the physiological function of NK cells and the 
mechanism of removal for certain tumor cells or other virally infected cells is still not well 
understood. 
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Figure 2.3 Immune response by a T lymphocyte with antigen presentation process [2] 
 
2.3.2 Antigen/Antibody Reactions  
 An antigen (Ag) or immunogen is any substance that induces the formation of antibodies 
and causes an immune response, when introduced parenterally into an animal. Alternately, an 
antigen, also known as an antibody generator, is any molecule which can stimulate antibody 
generation or generate an immune response [9]. 
 An antibody (Ab) or immunoglobulin (Ig) is a protein that can be used by the immune 
system to identify foreign objects. Antibodies, or immunoglobulin, have two large chains and 
two small light chains as a one unit. Antibodies can be classified into three types of structures 
based on the number and structure of the chains - one unit of two coupled heavy and light 
chains (monomers), two units of coupled chains (dimers), and five units (pentamers). 
Moreover, based on the isotypes of the two heavy polypeptide chains, immunoglobulin can 
also be divided into five subclasses IgA (alpha), IgD (delta), IgG (gamma), IgE (epsilon), or 
IgM (mu). There is a particular region which can bind with an antigen, the fragment antigen 
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binding, or Fab, which is located at the end of each light and heavy chain couple. [10, 11] 
The basic structure of an antibody is shown in Figure 2.4. 
 For the binding of antigen-antibody pair, the following conditions are required. First, 
complementarity and specificity of the antigen and antibody are required conditions for the 
reaction. Second, the antigen and its specific antibody need to be physically close together 
(less than 5 nm.) Third, the affinity between the antibody and its particular antigen should be 
high. Fourth, the number of multivalent sites needs to be approximately the same. Fifth, the 
concentration of antigens and antibodies needs to be suitable. Sixth, a proper environment is 
necessary. 
 The fundamental concept of antigen-antibody reaction is a lock and key fit; each antibody 
reacts with only its specific antigens. However, there is a cross reactivity; an antibody can 
bind not only with its specific antigen but also with an antigen which has a structure similar 
to the specific antigen.  
 
 
 
(a) (b) 
Figure 2.4 (a) a basic structure of immunoglobulin [11] and (b) ribbon drawing of a antibody 
(IgG) [12] 
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 Antigen-antibody binding is a physio-chemical reaction. All forces except covalent 
binding contribute: hydrogen bonds, electrostatic forces, van der Waals bonds, and 
hydrophobic bonds. The antigen/antibody reaction is reversible under certain conditions, 
such as pH, temperature, ion concentration, or agitation.  
 Antigen-antibody binding is a two step process. The first step is an encounter complex 
step which means specific antigen and antibody molecules simply encounter each other and 
form an encounter complex: Ag + Ab  AgAb. The second step is the cell binding step, 
which needs electrolytes (Na, Cl, H, Mg, K, etc.): AgAb  C. Ag is antigen, Ab is antibody, 
AgAb is the encounter complex stage, and C is the bound stage. 
 
2.4 Transportation of Blood Cells in the Human Body 
2.4.1 Fahraeus Effect and the Marginal Plasma Layer 
 The hematocrit, the ratio of red blood cells to whole blood, is very important in defining 
the behavior of the blood cell flowing in a vessel. The hemacorit depends on the tube 
diameter, which is called the Fahraeus effect, shown in Figure 2.5. In the range of 15~500 
μm diameter of capillaries, the hematocrit in a capillary tube, HT, is smaller than that in the 
feed and discharge tubes.  
 The magnitude of the Fahraeus effect decreases as the tube diameter decreases and the 
maximum effect occurs for approximately a 15~20 μm diameter tube. Figure 2.6 shows the 
Fahraeus effect based on the capillary tube diameter.  
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Figure 2.5 Schematic illustration of the Fahraeus effect with arbitraily assumed velocity of 
cells, Vc, and velocty of the plasma, Vp. (Black dots indicate red blood cells) [13] 
 
Figure 2.6 Fahraeus effect as a function of the capillary diameters (HT: Tube Hematocrit, HD: 
Discharge Hematocrit) [13] 
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Figure 2.7 The Fahraeus-Lindquist effect [13] 
 
 Due to the Fahraeus effect, decreasing the tube diameter decreases the viscosity of the 
blood which is called the Fahraeus-Lindquist effect (see Figure 2.7.) The relative apparent 
viscosity of the blood decreases as the tube diameter deceases until a tube diameter of 
aprroximately 4-6 µm.  
 Red blood cells tend to flow at the core of a channel due to their size, shape, and 
deformability. Due to this axial accumulation of red blood cells, a thin cell free layer, also 
called the plasma layer, is created in the channel. The thickness of the plasma layer is a 
function of the tube diameter and the hematocrit. Due to the marginal plasma layer, the 
viscosity at the core of a channel is higher than the viscosity near the wall. 
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 Marginal zone theory is used to characterize the Fahraeus-Lindquist effect. From 
marginal zone theory, viscosity is a function of the hematocrit, blood velocity, plasma layer 
thickness, and tube diameter. The thickness of the plasma layer can be estimated [1, 13-15].  
2.4.2 Effect of Erythrocyte or Leukocyte Rolling 
 Erythrocytes tend to flow at the fastest position in a vessel along the center axis. This 
axial accumulation creates plasma skimming or plasma layer in a vessel or in a channel.  
 The plasma layer may not help the lateral migration of the leukocytes, but the axial 
accumulation of erythrocytes forces the leukocytes to migrate toward the wall and helps the 
leukocytes encounter and roll along a channel wall [16-20]. 
2.5 Circulating Human Breast Cancer Cell and EpCAM 
 Circulating tumor cells, CTCs, exist at the early stage of tumor development and are very 
rare events: there are just a few CTCs in 1 mL of blood [21-23]. Even through some CTCs 
die during migration, other CTCs stay alive for several years and may cause macrometastases 
[24]. After the earliest stage of tumor development, the tumors grow rapidly [25]. Therefore, 
early stage cancer diagnosis is very important and detecting CTCs may be a key to early 
diagnosis.  
 EpCAM (Epithelial Cell Adhesion Molecule), also known as GA733-2, KSA, CD326, 
ESA, or 17-1A antigen, is one of the powerful biomarkers for breast cancer because in a 
peripheral blood CTCs express the EpCAM antigen. CTC detection can give a great 
opportunity for easy and simple diagnosis at an early stage. EpCAM can be used as a 
biomarker for other tumor cells [26-28].  
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2.6 Review of CTC Separation or Capture in BioMEMS 
 BioMEMS technology has been developed for cell separation or capture applications 
because it offers the advantages of a small sample volume, portability, low cost, easy sterility, 
and potential integration. Cell separation using BioMEMS can be classified as size-based, 
optically-based, or affinity-based approaches. Each method has advantages and 
disadvantages, such as sensitivity, flow rate, or recovery rate. Therefore, reviewing the 
current technology is necessary for CTC detection or capture research. 
2.6.1 Size-Based Approach 
 Size based CTC separation was tried for cell separation using the size differences 
between CTCs and human blood cells. However, the sample required very high pre-dilution 
and have purity issues. Not only the target cell but also other blood components were 
captured or trapped.  
Mohamed, et al. (2004) demonstrated separation of metastatic cancer cells from 
peripheral blood using parallel arrays of posts as obstacles [29]. The distance between the 
parallel channels and the depth of the channels was from 2.5 ~ 20 μm for different size of 
cells. Figure 2.8 (a) is an SEM (Scanning Electron Microscope) image of the micro obstacles. 
Separation took 2 ~ 3 hours for 2 mL of whole blood, without dilution. However, the 
separation efficiency was not clearly indicated and recovering the separated cells could be an 
issue.  
 Sethu et al (2006) introduced separation of leukocytes from whole blood using a micro 
diffusive filter [30]. Figure 2.8 (b) shows the design. The operating flow rates were 5, 7, and 
12 μL/min and more than 10% of leukocytes passed through sieves at 7 μL/min. 
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(a) (b) 
   
(c) 
Figure 2.8 Size based separation using (a) micropost obstacles [29], (b) micro diffusive filter 
[30], and (c) 3D microfilter separation [31] 
 
 Zheng et al (2010) fabricated a 3D microfilter device for CTC capture from blood [31]. 
The recovery rate was acceptable (85.6%) with a very high flow rate (1.8 ~ 3 mL/min). 
Figure 2.8 (c) shows the design and captured CTC on the filter. However, the 3D microfilter 
deivce required 9 X sample dilution and limited sample volume (up to 1 mL) to avoid 
clogging with leukocytes. 
2.6.2 Optically-Based Approach 
 A micro fluorescent activated cell sorter, μFACS, which is based on fluorescence 
technology, was demonstrated by Wolff et al (2003) to sort fluorescent latex beads from 
chicken red blood cells [32]. Figure 2.9 shows the simple concept of the μFACS. The flow 
rate was 0.11 μL/sec which is very high compared to other methods. However, it was not  
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Figure 2.9 Micro fluorescent activated cell sorter [32] 
 
demonstrated with real biological material and also it was not tested or certified for rare cells 
such as CTCs in whole blood. 
2.6.3 Affinity-Based Approaches 
 Affinity-based cell separation or capture uses the immune response, or antigen/antibody 
reaction. The affinity-based methods can be divided into antibody coated magnetic attraction 
or antibody functionalized surfaces. Furdui and Harrison (2004) introduced a magnetic 
attraction method using antibody coated magnetic beads [33]. In Figure 2.10 (a), a Y-channel 
microfluidic device separated T cells from whole blood with to a 40% efficiency at a 3 
μL/min flow rate. 
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(a) (b) 
Figure 2.10 Magnetic separation method by (a) Furdui and Harrison`s Y-channel device to 
separate T cells from blood using magnetic beads [33] and (b) leukocytes separation from red 
blood cells on a planar surface [34] 
 
Inglis at al (2004) showed that separation of leukocytes from red blood cells on the planar 
magnetic stripes. In the Figure 2.10b, the target cells were labeled with CD45 conjugated 
nanobeads and captured at a velocity of 110 μm/s on stripes of different angles [34]. 
 Cell separation using antibody functionalized polymer surfaces was demonstrated by 
Feng, et al. (2003) [35]. MCF-7 cells were captured on an anti-EpCAM coated polymer 
channel at a 2 mm/s velocity which was selected as an optimal velocity by modeling the 
antibody-antigen reaction..  
 Nagrath, et al. (2007) showed isolation of CTCs from human whole blood using a silicon 
CTC chip containing anti-EpCAM coated microposts [36]. The maximum recovery rate was 
65% with 1 mL/hr flow rate. Figure 2.11 (a) shows the experimental set up, the CTC chip, 
and the microposts. 
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(a) (b) 
  
(c) (d) 
Figure 2.11 CTC isolation using antibody coated micro device with (a) microposts etched 
CTC chip [36], (b) multiple sinusoidal channels [37], (c) Herringbone shape PDMS device 
[38], and (d) Cell capture-agent-coated nanostructured silicon substrate with chaotic mixing 
chip [39] 
 
 Adams, et al. (2008) introduced a polymer high throughput cell capture device using 51 
parallel sinusoidal channels to increase the flow rate [37]. The recovery rate was over 95% at 
a 32 μL/min flow rate. The simple geometry of the device and concept are shown in Figure 
2.11 (b). 
 Stott, et al (2010) used polydimethylsiloxane (PDMS) herringbone shape chip to generate 
microvortices [38]. The capture efficiency was increased by 26% compared to the CTC chip 
from Nagrath, et al. but the flow rate was low, < 2.5 mL/hr. Figure 2.22 (c) shows the device 
and herringbone shapes on the channel top. 
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 Wang, et al (2011) introduced cell capture-agent-coated nanostructured silicon substrate 
with a chaotic mixing chip [39]. The nanostructure increased the capture efficiency and the 
chevron shape chaotic mixer improved the encounter ratio. The device and nanostructures are 
shown in Figure in 2.11 (d). The recovery rate was 95% but the flow rate was 1 mL/hr which 
is not sufficient for clinical uses. 
 Affinity-based separation method has a high recovery rate. However, the maximum flow 
rate is not acceptable for clinical use. It would take over 4 hours to test a 7.5 mL sample 
volume even with the fastest design. 
2.6.4 Other Approaches 
 Hydrophoretic filtration was demonstrated to separate white blood cells from red blood 
cells based by Choi, et al. (2007) [40]. The flow rate was 1 μL/min for leukocyte isolation 
which gave about 58% of the isolation efficiency and a recovery rate of over 70%. See 
Figure 2.12 (a). 
 Shevkoplyas, et al. introduced a very interesting method of autoseparation of leukocytes 
from whole blood [20]. The principle of the autoseparation was leukocyte margination and 
plasma skimming which lead to leukocyte rolling in human blood vessels. The depth of the 
device was 10.3 μm which was similar with average diameter of leukocyte. Most of the 
leukocytes were pushed to the nearest sidewall because flexible erythrocytes tend to flow at 
the core of the channel, collide with leukocytes, and force the leukocytes to migrate laterally. 
Even through the flow rate was very low (approximately 0.54 nL/s for a 70 μm wide channel 
inlet), this approach may be valuable for the design of a cell separation device. Figure 2.12 (b) 
shows the location of the leukocytes in the channel and the device design. 
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 Moon, et al. (2011) developed a cell separation device using multi-orifice flow 
fractionation (MOFF) and dielectrophoresis (DEP) [41]. The MOFF can relocate 
microparticles or cells laterally because of hydrodynamic inertial force. The DEP force 
moves the target cell only because only the large target cells take the sufficient attractive 
force. The device could reach 126 mL/min flow rate and the recovery rate was 75.81%. 
However, it required very high low concentration of blood cells. The concentrations of 
erythrocytes and leukocytes were less than 1% and 0.01% respectively compare to 
concentration of normal human blood. Figure 2.12 (c) shows the device and the separating 
target cells in the device. 
2.6.5 Comparison of Current Research Methods 
 Cell separation technologies using BioMEMS have been developed by many researchers. 
However, it is still a question, especially for rare cells such as CTCs, whether any method or 
device can be suitable for a portable device or for a clinical use or not. The issues are 
recovery rates and low flow rates which makes the micro devices unacceptable for use at the 
point-of-care (POC.) The affinity-based approaches have high recovery rates compared to 
other methods but the flow rates are still an issue. Since the flow rate is not sufficient for 
clinical use and not applicable for a portable device, it is necessary to solve the problems. 
Table 2.1 compares the flow rates and recovery rates of different cell separation approaches 
using BioMEMS technology.  
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(a) (b) 
    
(c) 
Figure 2.12 Leukocyte separation using (a) hydrophoretic filtration [40], (b) lateral migration 
of leukocyte [20], and (C) MOFF with DEF [41] 
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Table 2.3 Comparison of flow rates and recovery rates of BioMEMS devices 
Approaches or 
Principle 
Basic Method or Technology 
Recovery 
Rate 
Flow Rate 
Size based 
Micropost obstacle arrays Low High 
Micro diffusive filter Medium 7 μL/min 
3D microfilter (9X dilution) High (86%) 3 mL/min 
Optical based Fluorescent label N/A 
Low 
(0.11 μL/sec) 
Affinity based 
Magnetic beads Low (40%) 3 μL/min 
Magnetic stripes Low Low 
Antibody coated micro posts Medium (65%) 17 μL/min 
Multiple sinusoidal channel High (95%) 32 μL/min 
Nanostructure with chaotic mixer High (95%) 17 μL/min 
Hydrophoretic 
filteration 
Slanted obstacles Low (58%) 1 μL/min 
Axial accumulation 
of erythrocytes 
Daughter channels Low 3 μL/min 
MOFF with DEP 
hydrodynamic inertial force 
and DEP force (>100X dilution) 
High (76%) 126 μL/min 
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2.7 Commercial Technologies for CTC Detection 
Commercialized products for CTC detection are CellSearch (Veridex, Raritan, NJ, USA,) 
OncoQuick (Greiner BioOne, Frickenhausen, Germany;  Greiner Bio-One, Inc., Longwood, 
FL, USA,) AdnaTest (AdnaGen AG, Hanover, Germany; OncoVista, Inc., San Antonio, TX 
USA,) OncoCEE (Biocept, Inc., San Diego, CA, USA,) and On-Q-ity CTC Chip (On-Q-ity, 
Waltham, MA, USA) [42-45]. Table 2.4 shows the comparison of these CTC detection 
technologies.  
 CellSearch is the only instrument approved by the U.S. Food and Drug Administration`s 
(FDA) for metastatic breast, colon, and prostate cancer. It uses anti-EpCAM coated magnetic 
beads (iron particles) to separate CTCs from whole blood (7.5 mL) and detect the CTCs 
using fluorescent techniques with CK+, DAPI+, and CD45-. The recovery rate for high 
EpCAM expressing cells is over 75% but it was decreased to 42% for low EpCAM 
expressing cells. The recovery rate for 10 spiked CTCs was 100% with 30% initial sample 
preparation error [42-45]. 
 OncoQuick uses density gradient centrifugation for CTC separation and an immuno-
based technique for CTC detection. The recovery rate is 72 ± 18% (56~92%) from whole 
blood (15 ~ 30 mL) according to a manual from the company [45-47]. 
AdnaTest is undergoing FDA approval, and a  Phase II clinical trial protocol is finalized. 
It uses immunomagnetic beads with anti-EpCAM or 2 antiMuc-1 for CTC separation from 
whole blood (2 x 5 mL), followed by molecular analysis using reverse transcriptase-
polymerase chain reaction (RT-PCR.) The separated CTCs are lysed and semi-quantitative 
RT-PCR performed with three epithelial cell associated messenger RNAs (MUC1, HER2,) 
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and the surface glycoprotein GA733-2 to obtain the number of CTCs. It could detect 31~69% 
from metastatic breast cancer patients [48, 49]. 
OncoCEE and On-Q-ity use antibody coated micro posts in a microchannel to separate 
the CTCs and identify the CTCs using fluorescence technique with CK, CD45, and DAPI. 
On-Q-ity additionally uses the size difference between CTCs and blood cells by using the 
gaps between the posts. On-Q-ity separates CTCs from 20~30 mL of whole blood without 
pre-treatment of the sample unlike OncoCEE which uses centrifugation. The recovery rate 
for high EpCAM expressing cells was >75% for both CTC chips. The recovery rate was for 
low EpCAM expressing cells was less than 50% for the Onco CEE CTC chip and higher than 
50% for the On-Q-ity CTC chip. In the case of ten spiked CTCs, the recovery rate was less 
than 50% for both CTC chips [43, 50, 51].  
Table 2.4 Comparison of commercial products 
 
Brand Method 
Detection/ 
Identification 
Sample 
Volume 
Recovery Rate 
CellSearch 
Immunomagnetic 
bead 
Fluorescence 7.5 mL 
>75% for high EpCAM cell 
(<50% for low EpCAM cell) 
OncoQuick Density gradient Immuno-based 15~30 mL >70% (from catalog) 
AdnaTEST 
Immunomagnetic 
bead 
Molecular 
analysis 
2 x 5 mL 
31 ~ 69% for clinical 
detection 
OncoCEE 
Immuno micro 
channel with posts 
Fluorescence 10 mL 
>75% for high EpCAM cell 
(<50% for low EpCAM cell) 
On-Q-ity 
Immuno micro 
channel with posts 
Fluorescence 20~30 mL 
>75% for high EpCAM cell 
(>50% for low EpCAM cell) 
 
2.8 Direction of Future CTC Capture Devices 
Current technologies for CTC capture were summarized and commercial products were 
introduced, but do not meet needs for clinical use and point-of-care (POC) applications. The 
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flow rate, recovery rate, and purity are still under the requirements. Size-based approaches 
could not satisfy the purity issues and requires pre-treatment of sample. Affinity-based 
approaches have a limited flow rate. Commercialized products have limited the flow rates 
and capture efficiencies. None of the approaches or products can be used for portable or POC 
application. The limitations of current methods include low flow rates, low recovery rates, 
low purity, and the need for pre-treatment of the sample that must overcome. Moreover, 
molecular analysis needs to be performed downstream to eliminate false-positive results and 
to obtain more specific and detailed information after target cell capture. 
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CHAPTER 3: DESIGN AND SIMULATION 
 
3.1 Design Concept for a High Flow Rate Device 
3.1.1 Sample Volume for Circulating Tumor Cell Detection 
 Circulating tumor cells, CTCs, in human peripheral blood are very rare events, 1 ~ 2 
CTCs in 1 mL circulating blood. This low concentration of CTCs requires a large sample 
volume to ensure reliable detection. The typical sample volume for blood-based tests requires 
7.5 mL to detect early stage cancer or to decide the probability of survival [1-4].  Current 
microdevices for cell capture usually operate at very low flow rates for maximal recovery 
rate. Therefore, to reliably detect CTCs in normal sample volumes of whole blood in a 
reasonable time (10 minutes), design of high a speed micro device is essential and a 
significant challenge. 
3.1.2 Design Target and Constraints 
 Design of a capture device should consider the function, fabrication method, and 
applications. The target is a high flow rate device for fast target cell capture from a relatively 
large volume of whole human blood for fast diagnosis or portable applications. The inlet 
flow rate is determined as 0.75 mL/min (12.5 mm
3
/sec) which will process the required 
sample volume (7.5 mL) in ten minutes. However, cell capture using antigen/antibody or 
aptamer reactions needs a low velocity to have a sufficient duration for binding to occur. The 
linear velocity for cell capture was selected in a range of 1~2 mm/sec based on previous 
studies with EpCAM [5, 6]. Therefore, the linear velocity in the capture area, a 
functionalized microchannel, has to be 1~2 mm/sec for maximum cell capture even though 
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the flow rate at the inlet of the device is 0.75 mL/min. Moreover, the size of the channel 
cross-section has to be minimized to maximize the encounter rate and it also needs to be 
large enough to avoid clogging. The mean diameter of CTCs in human blood is 30 μm in 
some cases of patients [7].  The diameter of CTCs is usually 10 ~ 30 μm. Therefore, one 
dimension of the channel (width or depth) should be at least 30 μm to avoid blockage.  
 Maximizing the encounter rate is one of the main objectives, because contact between the 
target cells and the functionalized channel walls is the first step in the antigen/antibody 
reaction. However, cells tend to flow at the center of the channel because of the parabolic 
velocity profile in laminar flow and the cell-free plasma layer which is formed in blood flow 
[8]. Moreover, lateral movement of the target cells is not easy to predict or control in a 
straight microchannel. A solution for these complicated issues is manipulating the velocity 
profile. If the velocity profile is not a parabola in a laminar flow, the target cells can be close 
to the channel wall and the encounter rate will be maximized. Manipulation of the velocity 
profile can be realized by adding another narrow channel or adding a small port in the main 
channel. Post arrays in a microchannel can change the velocity profile and enlarge the 
surface area, but the posts will reduce the cross-sectional area and lead high mean velocity to 
obtain high flow rate. 
 The velocity vector of the fluid can be changed if there is more than one outlet to a single 
channel. The velocity profile at a near channel wall in a single channel and a channel with 
narrow port are shown in Figure 3.1(a) and 3.1(b) respectively.  
The size of the narrow gap or port needs to be controlled to keep the target cells in the 
capture, or main, channel. Otherwise, the target cells may escape through the narrow gap or 
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(a) 
 
(b) 
Figure 3.1 Velocity profile a near wall (a) in a single channel without port and (b) in a single 
channel with a port 
   
the port. Moreover, the magnitude of the velocity or pressure gradients between the main 
channel and the gap and the pressure drop in the narrow gap or side channel need to be 
considered. The pressure drop governs the flow rate in the narrow gap, and the flow rate 
dominates the lateral component of the fluid velocity vector. A high lateral velocity 
component forces the target cells to deform and flow out through the gap even if the cell is 
larger than the gap.  
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 A conceptual design is shown in Figure 3.2. Using a narrow gap will decrease the volume 
of the sample in the main channel and increase the concentration of the target cells since 
other components, including plasmas, platelets, and red blood cells, in the blood should be 
filtered out through the narrow side channels. Therefore, a high flow rate can be realized with 
a high recovery rate. From an application point of view, a smaller device, with a small 
footprint, is preferred.  
 A small device for cancer cell capture can be integrated in a blood collection tube or 
needle and it can also be combined with multi well titer plates. Therefore, the length of the 
device needs to be less than 10 cm to be an integrated device of the blood collection tube. 
Indeed, one of proposed targets of this project is a portable device for cancer diagnosis.  
 
Figure 3.2 Initial design concept – Main channel with narrow side channels 
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(a)  
 
(b) 
  
(c) 
Lt: Total length of the main channel c: Depth of main channel after Lv 
Lv: Length of variable depth section h: Initial depth of  the variable depth section 
W: Width of main channel g: Depth of side channel 
S: Width of side channel θ: Angle of variable depth section 
 
Figure 3.3 Initial design approaches and parameters (a) top view of the main and side 
channels, (b) side view of the channels, and (c)  front view of the channels 
 
 Fabrication of the device introduces multiple constraints on the design. The width of the 
main channel needs to be minimized to avoid deformation during thermoplastic fusion 
bonding. The depth of the main channel inlet should be large enough to minimize the inlet 
velocity with a 0.75 mL/min flow rate. The width of the side channels should have enough 
space for the milling process since the milling of the side channels on the mold insert need to 
be stepped, with different heights from the main channel to achieve a narrow gap.  
 There are conflicting requirements for the cross-section and the depth or width of the 
main channel. The inlet of the main channel should be large enough to minimize the inlet 
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velocity, but the main channel also needs to be small enough to maximize the encounter rate 
of the cells with the wells.  
 A variable cross-section for the main channel is one solution for achieving a high flow 
rate with a minimal inlet velocity in the entrance region and realizing a low depth for the 
main channel after the variable depth channel section to obtain the maximum encounter rate. 
Figure 3.3 shows a configuration with a variable depth main channel. It can also be used to 
control the lateral velocity of the side channel. The angle (θ) governs the pressure and 
velocity in the variable section.  
3.2 Determination of the Baseline Channel Sizes 
3.2.1 Side Channel Design 
 As a blood cell filter and velocity profile manipulator, the dimensions of the side channel 
have to be carefully determined to avoid the loss of the target cells and device rupture. The 
depth of the side channels should be small enough to avoid any loss of the target cells. The 
target cells for evaluating circulating human breast cancer diagnosis is the MCF-7 cell. The 
diameter of the MCF-7 cell is normally larger than 15 μm. Figure 3.4 shows the size of a 
cultured MCF-7 in a hemacytometer. The average size of circulating human breast tumor 
cells is around 30 μm in diameter [7]. Cells can deform under high pressure to pass through 
narrow gaps. Therefore, the depth of the side channels should be 10 μm or less.  
 The lengths of the side channels are determined by the resulting pressures and flow rates 
which are dependent on the angle of the variable depth section in the main channel. Multiple 
lengths of main and side channels were simulated using Fluent v6.3 (ANSYS, Inc., 
Canonsburg, PA, USA.) 
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Figure 3.4 Size of the MCF-7 cell line (Two MCF-7 cells are shown in the right picture.) 
  
The reservoirs for the side channels were located at the end of the side channels to obtain 
an even pressure distribution when the side reservoir works as suction port. The entrance 
region of the main channel has high pressure and a high flow rate, which decreases along the 
length of the main channel.  
3.2.2 Main Channel Design 
 The depth of the main channel should be small enough to maximize the encounter rate. 
One of the possible options is 30 μm for a maximum encounter and to minimize cell clogging 
issue. Conversely, it should be large enough to minimize the pressure drop at high flow rates. 
Therefore, a variable depth with a deeper entrance region and a shallower capture region 
were applied. Multiple depths of the main channel entrance were simulated to estimate the 
pressure variation and the flow rate (or maximum velocity) along the main channel. A wider 
main channel allows a higher flow rate and lower pressure drop. However, the wider channel 
can deform more during thermal bonding. Consequently, the width of the channel cannot be 
larger than 500 μm. Due to deformation, a 300 or 400 μm width of the main channel was 
chosen. Even though the width of main channel was 300 ~ 400 μm, the length between 
51 
 
 
contact points which support the cover slip during thermal bonding of the main channel can 
be closer to one millimeter since the support structures are outside of the side channels, 
which are connected to the main channel.  
 The length of the variable depth section is very critical for the control of the pressure, the 
flow rate, and the velocity vector throughout the device. The length and the initial depth of 
the variable depth section determine the angle (θ) of the variable depth section. To achieve 
constant pressure at the side channel along the main channel, the length of the variable 
section needs to be large enough or the angle (θ) needs to be small to avoid a sudden velocity 
increase.  
3.2.3 Encounter Rate and Duration Time 
 Encounter is the first step in an antigen/antibody reaction. To maximize the encounter 
rate, the size of the main channel and the velocity of the target cell need to be considered. A 
small channel and high velocity give a high encounter rate because cells pass by a large 
number of receptors and have a short distance to travel to them. However, a high velocity 
reduces the time during which the binding reaction can take place. Therefore, 30 μm was 
chosen for a high encounter rate, and less than 2 mm/s mean velocity was chosen as the 
target velocity. The target flow rate of the main channel outlet was already determined since 
the main channel was 300 ~ 400 μm wide with a 30 μm depth and less than a 2 mm/s mean 
velocity. The flow rate in the main channel outlet needed to be less than 0.024 mm
3
/s or 0.2% 
of the inlet flow rate. Long side channels or a second set of side channels after the first 
section side channels can give the required low flow rate if the outlet flow rate after the first 
side channel is higher than the target flow rate. One design option for the high flow rate 
device for CTC capture is shown in Figure 3.5.  
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(a) (b) 
Figure 3.5 Design of the high flow rate device (a) the mold insert (b) half of the PMMA 
device 
 
3.3 Reservoir Design 
 Design of the inlet reservoir is very important, especially for rare cell capture, because 
target cells can be lost or clogged at the inlet reservoir if there is large misalignment between 
the center of the capillary and the reservoir center. Missing a single target cell can seriously 
affect the diagnostic result of the CTC capture due to the rarity the CTCs. For example, loss 
of one target cell can give more than 10% error for a 7.5 mL sample since the critical number 
of CTCs is 5 in 7.5 mL. 
3.3.1 Dead Volume and Pressure Drop 
 The reservoir, which connects the capillary and channel, usually creates a dead volume 
which may cause vortical flow in the reservoir. The dead volume may produce cell loss or air 
bubbles. Trapped air may interfere with cell capture or lead to inaccurate control and slow 
response of the sample flow. The reservoir is also one of the sources of higher pressures due 
to the dramatic geometry change from a macro capillary to a microchannel [9, 10]. If a 
mismatch between the reservoir core and a capillary tube connection hole is large, cell 
Variable Depth of Main 
Channel 
Side Channel 
Main Channel 
Drain Reservoir 
Inlet Reservoir 
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transportation cannot be done properly because the capillary can be partially or totally 
blocked. To avoid unwanted cell trapping or cell clogging, the hole needs be located at the 
center of the reservoir with minimal burrs. 
3.3.2 Semi-Automatic Positioning of Reservoir Core for Drilling  
 Drilling of the reservoir is also very important for rare cell experiments because improper 
drilling will increase the pressure drop and target cell loss. Drilling should minimize the burr 
and the drilled hole needs to be located on the centerline of the reservoir. To locate the hole 
at the center of the reservoir, a drill guide was designed. The guide semi-automatically helps 
to locate the drill bit at the center of the reservoir. Once the tip of the bit is inserted in the 
drill guide hole, the drill bit is pushed toward the center by the polymer device. A reservoir, 
mold insert, hot embossed polymer, and drilled hole are shown in Figure 3.6.  
 
   
(a) (b) (c) 
Figure 3.6 Reservoir design and drilling for reduced cell loss (a) mold insert, (b) hot 
embossed PMMA, and (c) center drilled hole with less than 10 μm mismatch 
 
3.4 Simulation of a High Flow Rate Device 
 It is essential to predict the fluid behavior including velocity vectors, path lines, flow 
rates, and pressure in the channel for optimum design. Computational fluid dynamics (CFD) 
was used to estimate the performance and to optimize the device dimensions before actual 
Drilling guide 
Reservoir structure 
Drilling guide hole 
Reservoir 
Drilled hole 
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fabrication. The Fluent program (Fluent v6.3.26, ANSYS, Inc., Canonsburg, PA, USA) was 
used for the simulations. Gambit (Gambit v2.46, ANSYS, Inc., Canonsburg, PA, USA) and 
Tecplot (Tecplot v360, Tecplot, Inc., Bellevue, WA, USA) were used for meshing and post 
processing.  
 Two baseline configurations were initially studied, as shown in Figure 3.7. The first had a 
constant depth main channel and the second incorporated a variable depth main channel. A 
parametric study was used to determine the final dimensions (depth, length, width of 
channels.)  
 
(a) 
 
(b) 
Figure 3.7 Baseline configurations for simulation: (a) Uniform depth main channel and (b) 
Variable depth main channel 
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 Meshing and Boundary Conditions 3.4.1.
Meshing was done using Gambit. The mesh type was hexahedral cells and it was 
manually generated. The size of each cell was 10 μm in the x- and y-directions and 2 ~ 10 
μm in the z-direction. The maximum cell size was 10 μm on all sides. The cell size was small 
enough to obtain general information about local pressures and velocities. Typical hexahedral 
cells and the reference point with X-, Y-, and Z- directions are shown in Figure 3.8. Water 
was used for working fluid and all other unmeshed surfaces were defined as solid walls 
except one inlet and three outlet surfaces.  
 A velocity inlet was used to establish the inlet conditions and give a constant inlet flow 
rate. A pressure outlet was used to calculate the flow rate based on the pressure differences at 
each outlet, including the side and main channels. All outside surfaces were set to 
atmospheric pressure.  
  
  
Figure 3.8 Typical hexahedral 3D mesh used for simulations 
Y 
X Z 
Reference 
Point 
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 Inlet velocity was selected based on the inlet cross section area to provide 0.75 mL/min 
or 0.075 mL/min to check the flow rate effect. The Fluent solver was 3ddp which runs a 
three-dimensional, double-precision solver. Convergence criteria for all residual variables (x-, 
y-, and z-velocities and continuity) were given 10
-7
 to get accurate results. To check the 
effect of the mesh size, multiple mesh sizes were simulated. The error for different meshes 
was tested for pressure and velocity. Results for the medium and fine meshes were very 
acceptable. One example of residual monitoring for convergence as a function of the number 
of iterations and the mesh sensitivity are shown in Figure 3.9 and Figure 3.10, respectively. 
Mesh size effects were tested by comparing the velocity and pressure from very coarse, 
coarse, medium-coarse, medium, and fine mesh conditions.  
 High Flow Rate Device Version One (HFRD1) 3.4.2.
 Simulations were performed for the two baseline designs in Figure 3.7. Design of a 
constant depth main channel, Figure 3.7 (a), was simulated for the flow behavior in the main 
channel with side channels and the high flow rate application.  
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Figure 3.9 Residual monitoring with iterations 
 
 
 
(a) 
 
 
(b) 
Figure 3.10 Mesh size effects on (a) velocity and (b) pressure: very coarse mesh (43,600 
cells), coarse mesh (222,400 cells), medium-coarse mesh (410,100 cells with non-uniform 
mesh shape), medium mesh (356,000 cells), and fine mesh (818,000 cells) 
 
Medium-coarse mesh 
Very coarse mesh 
Coarse mesh 
Medium mesh 
Fine mesh 
Medium-coarse mesh 
Very coarse mesh 
Coarse mesh 
Medium mesh 
Fine mesh 
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 Simulations of the variable depth main channel, Figure 3.7 (b), werealso computed to 
minimize the maximum pressure and to maximize the encounter rate of the target cells with 
the wall with minimum flow velocity at the main channel outlet. The high flow rate devices 
version one (HFRD1) had 10 μm deep side channels. The working solution was water. 
 Constant Depth Main Channel 3.4.2.1
 For a constant depth main channel, multiple cases, C1~C4, were initially simulated. The 
dimensions and inlet flow rates for each case are shown in Table 3.1. The depth of the main 
channels was 30 or 50 μm and the depth of side channel was 10 μm. The total length was 
2000 or 4000 μm. The length of the side channel was 400 μm less than Lt; the front 200 μm 
was for the entrance section for fully developed flow and the last 200 μm was also for fully 
developed outlet flow or a further connection. The inlet flow rate was 0.75 mL/min or 0.075 
mL/min.  At 0.75 mL/min, the pressure and velocity were very high, as shown in Figure 3.11. 
The target flow rate (0.75 mL/min) was obtained using ten parallel devices with the 0.075 
mL/min. The cases C1~C4 had the same channel widths of (400 μm for the main channel, 
100 μm for the side channels.)  
Table 3.1 Dimensions and inlet conditions for constant depth main channels (The width of 
the main channel is 400 μm, the depth of side channel is 10 μm, and the initial depth of the 
main channel is 30 or 50 μm.) 
Cases (g=10 μm) C1 C2 C3 C4 
Width of main channel (W) [μm] 400 400 400 400 
Depth of main channel (D) [μm] 30 30 30 50 
Length of side channel (Ls) [μm] 1,600 1,600 3,600 1,600 
Total length (Lt) [μm] 2,000 2,000 4,000 2,000 
Inlet flow rate (Qin) [mL/min] 0.075 0.75 0.075 0.075 
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 Figure 3.11 shows the pressure and velocity differences as a function of the inlet flow 
rate. The independent axis indicates displacement from the inlet to outlet and the Y-axis is 
the value of the total pressure or velocity. The X-, Y-, and Z-direction and the reference point 
are shown in Figure 3.8. The coordinates X, Y, and X indicate length, width, and depth of the 
channel respectively. The pathline was a line along the center of the main channel in the X-
direction which has the maximum pressure and velocity. The center line for cases C1~C3 is 
15 μm distance in Z-direction from the reference point because C1~C3 has 30 μm depth of 
main channel.  The center line for case C4 was 25 μm distance in Z-direction from the 
reference point because C4 had 50 μm depth of main channel.  
The 30 μm deep channel could not be used for high flow rate (0.75 mL/min) because the 
pressure and velocity at near the inlet were very high. Too much pressure leads to a high risk 
of rupturing the seal. Moreover, the outlet velocity was also too high in both cases C1 and 
C2. High velocity will reduce the time for antigen/antibody binding in the capture area.   
 Figure 3.12 shows the pressure and velocity difference based on the depth of the main 
channel and length of the channel. The maximum pressure changed, not due to the different 
lengths but due to the different depths of the channels. The outlet velocity depends on the 
depth and length of the channels.  
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(a)  
  
(b)  
 
Figure 3.11 Comparison of flow rates: 1.25 [mm
3
/sec] (C1) vs. 12.5 [mm
3
/sec] (C2) with 
same dimension: (a) pressure difference and (b) velocity difference 
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(a)  
 
 
(b) 
 
Figure 3.12 Comparison by depth and length of the main channel with same inlet flow rate 
1.25 mm
3
/sec (or 0.075 mL/min): (a) pressure difference and (b) velocity difference 
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 Table 3.2 summarizes the simulation results for the constant depth channel. „Cross Area‟ 
is the area of the cross-section at each inlet and outlet. „Main Inlet‟ or „Main Outlet‟ means 
the inlet or outlet surface of the main channel and „Side Outlet‟ is the outlet surface of the 
side channels. Velocity is the mean velocity at each surface. The capital letters „A‟, „Q‟, and 
„V‟ indicate cross sectional area, flow rate, and mean velocity respectively. Small letters („o‟, 
„s‟, and „in‟) indicate surface of main channel outlet, side channel, and main channel inlet 
respectively. For example, As is cross sectional area of side channel, Qin is flow rate of main 
channel inlet, and Vo is velocity of main channel outlet.  
 
Table 3.2 Results of the constant depth main channel 
Parameter Model 
Constant Depth Main Channel 
C1 C2 C3 C4 
Cross Area (A) 
[mm
2
] 
Main Inlet (Ain) 0.012 0.012 0.012 0.020 
Side Outlet (As) 0.032 0.032 0.072 0.032 
Main Outlet (Ao) 0.012 0.012 0.012 0.020 
Area Ratio  As / Ain 2.67 2.67 6.00 1.60 
Flow Rate (Q) 
[mm
3
/s] 
Main Inlet (Qin) 1.250 12.504 1.250 1.250 
Side Outlet (Qs) 1.033 10.141 1.236 0.544 
Main Outlet (Qo) 0.218 2.363 0.014 0.706 
Flow Rate Ratio (%) Qo / Qin 17.43 18.90 1.12 56.51 
Velocity (V) 
[mm/s] 
Main Inlet (Vin) 104.20 1042.00 104.20 62.50 
Side Outlet (Vs) 32.26 316.89 17.17 16.99 
Main Outlet (Vo) 18.16 196.95 1.17 35.32 
Velocity Ratio (%) Vo / Vin 17.43 18.90  1.12  56.51
Maximum Pressure [Pascal] 1374.26 14014.86 1388.69 512.20 
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 Figure 3.13 shows the streamlines for each case to estimate the location of the target cells 
in the channel. The location of the target cells will not be exactly same as the streamlines or 
pathlines, but it may follow the trajectory. It is very important to estimate the location of 
target cells to maximize the encounter rate. For example, in Figure 3.13 (a), „C1‟, and Figure 
3.13 (b), „C2‟, are not much different even through the inlet velocity of the case „C2‟ is ten 
times higher than the case „C1‟. It is also similar result of flow rate ratio (%) or velocity ratio 
(%) between inlet and outlet for the cases „C1‟ and the case „C2‟ in Table 3.2. The location 
of the target cells may not depend on the inlet flow rate. The case „C3‟ in Figure 3.13 (c) 
shows that most of the streamlines flow through the outlet (unlike the case „C1‟ or „C2‟) 
because 98.88% of the inlet fluid flowed out the side channels. The case „C3‟ indicates that 
all of the target cells may encounter the side wall of the main channel. So, the longer channel 
may give a better chance of encounter on the side channel. In Figure 3.13 (d), „C4‟, shows 
that most of the streamlines flow through the main outlet unlike the other cases (C1~C3) 
because the over 56% of the inlet fluid flowed out through the main channel outlet. The case 
„C4‟, with a deep main channel, gave less chance of target cells encountering the side walls. 
Moreover, even though the inlet flow rate was 0.075 mL/min, the outlet velocity was over 35 
mm/s, which is too fast to capture target cells. The case study of the constant depth main 
channel, cases C1~C4, gave much valuable information on the flow behavior. The constant 
depth channel could not be used for high flow rate cell capture because the outlet velocity 
was too high even at the lower inlet flow rate, 0.075 mL/min and the pressure and inlet 
velocity were too high at the target flow rate of 0.75 mL/min. 
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(a) 
 
(b) 
Figure 3.13 Streamlines for each case to predict the location of target cell in the constant depth 
main channel: (a) case „C1‟, (b) case „C2‟, (c) case C3, and (d) case C4. The cases „C1‟ and 
„C2‟ show the effect of inlet flow rate, the length of the channel effect is shown between the 
cases „C1‟ and „C3‟, and the effect of the depth of channel is shown between the cases „C1‟ and 
„C4‟. (Continued) 
C2 
C1 
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(c) 
 
(d) 
Figure 3.13 Streamlines for each case to predict the location of target cell in the constant 
depth main channel: (a) case „C1‟, (b) case „C2‟, (c) case C3, and (d) case C4. The cases 
„C1‟ and „C2‟ show the effect of inlet flow rate, the length of the channel effect is shown 
between the cases „C1‟ and „C3‟, and the effect of the depth of channel is shown between the 
cases „C1‟ and „C4‟. (Continued) 
 
C3 
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 Variable Depth Main Channel 3.4.2.2
 The variable depth main channel configurations (identified as V1~V5 or N1~N3, shown 
in Table 3.3), were evaluated to overcome the limitations of the constant depth main channel, 
an unacceptable inlet/outet velocity and unreasonable maximum pressure. Two different 
types of the main channels were considered: 400 μm width with a 100 μm depth at the 
channel inlet, cases V1~V5 shown in Table 3.3, or a 300 μm width with a 150 μm depth at 
the channel inlet, for cases N1~N3 shown in Table 3.5. The depth of the side channel was 10 
μm for cases of V1~V5 and N1~N3. The total length of the main channel (Lt) was varied 
from 2000 to 8000 μm and the length of the variable depth section, (Lv) was 700 μm to 4800 
μm. The length of the side channel was 400 μm less than Lt; the front 200 μm was for the 
entrance section for fully developed flow and the last 200 μm was also for fully developed 
outlet flow or a further connection. The inlet flow rate was 0.75 mL/min (12.5 mm
3
/sec) for 
all cases. 
 
Table 3.3 Dimensions and inlet flow rate of the variable depth main channels. (The width of 
the main channel is 400 μm, the depth of side channel is 10 μm, and the initial depth of the 
main channel is 100 μm.) 
Cases (g=10 μm) V1 V2 V3 V4 V5 
Width of main channel (W) [μm] 400 400 400 400 400 
Depth of main channel inlet (D) [μm] 100 100 100 100 100 
Depth of main channel outlet (c) [μm] 30 30 30 30 30 
Length of variable depth section (Lv) [μm] 700 980 2,800 2,800 2,800 
Length of side channel (Ls) [μm] 1,600 1,600 3,600 5,600 7,600 
Total length of main channel (Lt) [μm] 2,000 2,000 4,000 6,000 8,000 
Inlet flow rate (Qin) [mL/min] 0.75 0.75 0.75 0.75 0.75 
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 Figure 3.14 shows the pressure and velocity at the center line of the main channel, which 
is expected to have the highest pressure and velocity. Five cases were simulated, shown in 
Table 3.3: three different lengths of variable depth section (700 μm, 980 μm, and 2800 μm) 
and four different total lengths of main channels (2000 μm, 4000 μm, 6000 μm, and 8000 μm) 
were considered. The outlet channel depth (or the depth after the variable depth section) of 
the main channel was 30 μm, and the initial depth of the main channel was 100 μm for all 
cases.  
 In Figure 3.14 and Figure 3.15 show the effect of the length of the variable depth section 
(Lv) and total length (Lt). When the length of variable depth section (Lv) was less than 40 
times the length of the initial depth of the variable depth section (Lv is less than 40•h or Lv < 
40•h), the maximum pressure was very high (4870 Pascal for V2 and 6313 Pascal for V1) at 
the channel inlet section and the velocity was increased until the fluid passes the variable 
section along the main channel (cases V1 and V2). For cases V1 and V2, The velocity 
increased due to the decreasing cross-sectional area of the variable depth section along the 
main channel. The angle of the variable depth section (h/Lv) had to be small enough to let the 
fluid smoothly pass through the side channels and to maintain the flow rate in the main 
channel. On the other hand, when the length of the variable depth section (Lv) was 40 times 
longer than the length of the initial depth of the variable depth section, Lv ≥ 40•h, there was 
no velocity overshoot (Cases V3~V5.) Increasing the total length of the main channel (Lt) did 
not change the pressure and velocity in the range of the variable depth section (Lv.)  
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(a)  
 
(b)  
Figure 3.14 (a) Pressure and (b) velocity information based on the variable depth section 
length (Lv) and the channel total length (Lt). The cases of the short length of the variable 
depth section give higher maximum pressure and velocity overshoot (See the cases of V1 and 
V2 in the graphs).   
 
V5 
V1 
V2 
V3 
V4 V5 
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Figure 3.15 Streamwise velocity through the potential contact line of the target cell; The 
cases of the short length of the variable depth section show velocity overshoot (See the cases 
of V1 and V2 in the graphs).  
 
 However, a longer total length gave a much lower outlet velocity. For example, the outlet 
velocity of case V3 was 60.48 mm/s and case V5 was 0.24 mm/s, shown in Table 3.4. One of 
the prospective target cell contact regions is near the side channel entrance of the main 
channel; the Y location can be 190 μm or -190 μm for 400 μm width of the main channel and 
the Z location can be -10 μm from the reference point in Figure 3.8. The streamwise velocity 
information at the prospective contact line of the target cell is shown in Figure 3.15. 
Velocities for the cases V3~V5 were constant over the range of Lv. 
 Figure 3.16 shows the pressure contour and velocity vector for the case of V1. There is a 
sudden velocity increase near the end of the Lv section which shows the highest velocity 
value in Figure 3.14(b) and Figure 3.15. Table 3.4 contains results for the variable depth 
main channel design with a 400 μm width main channel (W=400 μm and D=100 μm). 
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(a) 
 
(b) 
Figure 3.16 Pressure contour and velocity vector of V1 
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Table 3.4 Results of variable depth main channel with 400 μm width of the main channel 
Parameter Model 
Variable Depth Main Channel 
V1 V2 V3 V4 V5 
Cross Area (A) 
[mm2] 
Main Inlet (Ain) 0.040 0.040 0.040 0.040 0.040 
Side Outlet (As) 0.032 0.032 0.072 0.112 0.152 
Main Outlet  (Ao) 0.012 0.012 0.012 0.012 0.012 
Area Ratio  Ao / Ain 0.30 0.30 0.30 0.30 0.30 
Flow Rate (Q) 
[mm3/s] 
Main Inlet (Qin) 12.50 12.50 12.50 12.50 12.50 
Side Outlet (Qs) 9.740 8.870 11.774 12.454 12.497 
Main Outlet  (Qo) 2.760 3.630 0.726 0.046 0.0030 
Flow Rate Ratio (%) Qo / Qin 22.08 29.04 5.81 0.37 0.02 
Velocity  
[mm/s] 
Main Inlet (Qin) 312.50 312.50 312.50 312.50 312.50 
Side Outlet (Qs) 304.38 277.20 163.53 111.20 82.22 
Main Outlet  (Qo) 229.97 302.48 60.48 3.81 0.24 
Velocity Ratio (%) Vo / Vin 73.59 96.79 19.35 1.22 0.08 
Maximum Pressure [Pascal] 6313.4 4870.1 3590.9 3605.8 3581.7 
 
 Based on the velocity, pressure, and streamline information, the short variable depth 
channel, such as V1 and V2 in Table 3.3 and Table 3.4 were not suitable. The Lv needs to be 
at least 40•h (2800 μm with h = 70 μm, h=D-c in Table 3.3) to avoid the sudden velocity 
increase. Reducing the cross-sectional area or reducing the depth of the main channel in the 
variable depth section (Lv) causes a reduction in the volume per unit length in the main 
channel. The volume reduction rate must match the flow rate of the side channels to maintain 
the same velocity in the main channel. Therefore, the slope or angle (h/Lv) needs to be small 
enough. Otherwise, reducing the cross-sectional area in the main channel will increase the 
velocity due to conservation of mass or the continuity equation for an incompressible fluid. 
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(a) 
 
(b) 
Figure 3.17 Streamlines of (a) V2 and (b) V3, and pathline of (c) V4 (continued) 
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(c) 
Figure 3.17 Streamlines of (a) V2 and (b) V3, and pathline of (c) V4 (continued) 
 
 The maximum pressure was not significantly affected by the total length (Lt) or the slope 
(h/Lv) for the cases of V3, V4, and V5. However, the outlet flow rate and the outlet velocity 
of the main channel depended strongly on the total length (Lt) because the length of the side 
channel (Ls) increased as the total length of the main channel (Lt) increased (Ls was 400 μm 
less than the Lt.) In the cases V3 and V4 in Table 3.3, the outlet velocity of the main channel 
was higher than the target velocity, 2mm/s. However, it can be used for CTC capture 
application by adding a second side channel which has the same geometry as the constant 
depth main channel. The maximum pressure can still be an issue for maintaining the seals; 
the seal strength for this low aspect ratio may not be as strong as the seal for high aspect ratio 
structures due to the minimum temperatures and pressure conditions necessary during 
thermal bonding. Therefore, the depth of the bonding layer for the low aspect ratio case could 
not be more than that of the high aspect ratio structures to achieve minimum deformation. 
The inlet velocity was very high to achieve the required flow rate of 0.75 mL/min.  
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 To reduce the inlet velocity, maximum pressure, and deformation the inlet depth of the 
main channel was modified from 100 μm to 150 μm (from h=70 to h=120, h=D-c) and the 
width of the main channel was reduced from 400 μm to 300 μm (from W=400 to w=300). 
Since the cross-sectional area of the main channel entrance was increased, the inlet velocity 
and maximum pressure for the 0.75 mL/min flow rate were decreased. The Table 3.5 shows 
the dimensions for each case of modified new variable depth channel. The length of the side 
channel was 400 μm less than the total length of the main channel. The narrower main 
channel should have fewer deformation problems during the thermal bonding process. Three 
different lengths of the variable depth (N1, N2, and N3) were simulated to obtain better 
performance. 
 
Table 3.5 Dimensions and inlet flow rate of the modified variable depth main channels. (The 
width of the main channel (W) is 300 μm, the depth of side channel (g) is 10 μm, and the 
initial depth of the main channel (D) is 150 μm)  
Cases (g=10 μm) N1 N2 N3 
Width of main channel (W) [μm] 300 300 300 
Depth of main channel inlet (D) [μm] 150 150 150 
Depth of main channel outlet (c) [μm] 30 30 30 
Length of variable depth section (Lv) [μm] 3,600 4,200 4,800 
Length of side channel (Ls) [μm] 4,600 4,600 5,600 
Total length of main channel (Lt) [μm] 5,000 5,000 6,000 
Inlet flow rate (Qin) [mL/min] 0.75 0.75 0.75 
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(a) 
 
(b) 
Figure 3.18 Pressure and velocity information along the center line in the main channel for 
the modified new variable depth channel (w=300 and h=120) 
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Figure 3.19 Streamwise velocity information on the prospective target cell contact line for 
w=300 and h=120 
 
Figure 3.18 shows that the pressure and velocity for the modified new variable channel cases 
(N1~N3) were reduced. Moreover, the streamwise velocity information along the prospective 
target cell contact line or region is shown in Figure 3.19. In the case of N3 in Figure 3.19, 
there is no velocity increase. 
Based on the maximum pressure and velocity data, the case of N3 in the modified new 
variable depth main channel cases in Table 3.6 is suitable for a high flow rate design to 
capture CTCs. However, the outlet velocity is higher than the desired velocity for the 
maximum recovery rate. The detailed information about the flow rates and velocities at each 
inlet and the outlets are shown in Table 3.6. 
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Table 3.6 Results of cases N1~N3 (modified variable depth main channel with 300 μm width) 
Parameter Model 
New Variable Depth Main Channel 
N1 N2 N3 
Cross Area (A) 
[mm2] 
Main Inlet (Ain) 0.045 0.045 0.045 
Side Outlet (As) 0.092 0.092 0.112 
Main Outlet  (Ao) 0.009 0.009 0.009 
Area Ratio  Ao / Ain 0.20 0.20 0.20 
Flow Rate (Q) 
[mm3/s] 
Main Inlet (Qin) 12.50 12.50 12.50 
Side Outlet (Qs) 12.22 11.95 12.29 
Main Outlet  (Qo) 0.279 0.548 0.209 
Flow Rate Ratio (%) Qo / Qin 2.23 4.38 1.67 
Velocity  
[mm/s] 
Main Inlet (Qin) 277.78 277.78 277.78 
Side Outlet (Qs) 132.84 129.92 109.74 
Main Outlet  (Qo) 30.99 60.84 23.22 
Velocity Ratio (%) Vo / Vin 11.16 21.90 8.36 
Maximum Pressure [Pascal] 2765.02 2563.63 2424.93 
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Figure 3.20 Pathlines colored by time for case of N3 
 
Pathlines colored by time for case of N3 are shown in Figure 3.20. Most pathlines flow 
out through the side channels. The travel time for the target cell was extremely short (less 
than 0.02 second) from the inlet to the side outlet. So, there may not be enough time for 
antigen/antibody reactions. However, when the target cells contacted the side channel 
entrance, the target cells will stop at the collision point and give sufficient time for 
antigen/antibody reaction without rebounding due to the low elasticity of the cell.  
The lateral velocity was investigated at the moment of target cell collision or exclusion. 
The collision path line or prospective exclusion path line were the initial contact lines of 
target cell at the side channel entrance. It was determined 10 μm away from the side channel 
in the main channel and 10 μm below the top surface of the main channel. Figure 3.21 shows 
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the collision path line. Two phase flow simulations or cell capture experiments are needed to 
estimate the true location of the target cell collision with the wall. The axial and lateral 
velocities are shown in Figure 3.22 for cases V3~V5 and case N3 for comparison.  
 
  
Figure 3.21 Collision path line (X=10 µm and Y= 10 µm) and reference point in a cross 
sectional view of main and side channels  
 
3.4.2.3  Results of High Flow Rate Device Version One 
The „N3‟ configuration in Table 3.5 was selected because it gave a lower maximum 
pressure, inlet velocity, and potentially lower deformation during sealing process. It could 
reduce the 98.7% of flow rate and 81.6% of mean velocity which is shown in Table 3.6. 
However, the outlet flow rate is 0.2 mm
3
/s and mean outlet velocity is 23.33 m/s. To reduce 
the flow rate and the mean velocity at the main outlet region, the end of the main channel 
needed to be connected to secondary channels, such as a longer constant depth channel 
(C1~C4.) The effect of the longer channels (Lt and Ls) is shown in Table 3.2 (C1 and C3) 
and Table 3.4 (V3~V5). The outlet velocities from C1 to C3 in Table 3.2 or from V3 to V4 
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or V5 in Table 3.4 are exponentially reduced. Additionally, the depth of the second main 
channel can be 30 μm to avoid potential target cell loss. By manipulating the flow rate at 
each outlet, including the side and main channel outlets, the flow rate of each outlet and 
velocity vector in each region could be controlled and cell loss can be avoided because the 
lateral force and centrifugal force of the target cells can be controlled.  
 
(a) 
 
(b) 
Figure 3.22 Axial and lateral velocities on the exclusion path line (X=10 µm and Y= 10 µm) 
for (a) the case V3~V5 and (b) the case N3 
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 High Flow Rate Device Version Two (HFRD2) 3.4.3.
The second version of the high flow rate device (HFRD2) was designed and simulated 
because the first version (HFRD1) had target cell loss issues after demonstration. The 10 µm 
deep side channels in the HFRD1s allowed target cell loss through the side channels due to 
deformation of the target cells. The cross-sectional area for cases N1~N3 of the main channel 
inlet also limited the maximum flow rate. The depth of the side channels was reduced to 5 
µm for the HFRD2 and the cross-sectional area of the main channel inlet was increased. 
The design of the HFRD2 focused on overcoming the target cell loss, minimizing the 
mean axial velocity in the second channel, and reducing the lateral velocity along the 
exclusion path. The simulation conditions are shown in Table 3.7. 
Table 3.7 Simulation conditions for HFRD2 
SIMULATION CONDITIONS 
Goal High Flow Rate Microdevice to Capture Rare Target Cells 
Tool Gambit v2.4, Fluent v6.3, Tecplot 2008 
Design Target 
 Inlet flow rate: 0.75 mL/min 
 Mean outlet velocity of main channel: < 2 mm/s 
 Minimum lateral velocity at side channel: No target cell loss 
Constraints 
 Depth of main channel inlet: 130 μm to minimize inlet velocity 
 Depth of second section: ~ 30 μm for the maximum recovery rate 
 Depth of side channel: 5 μm to avoid target cell loss 
 Width of side channel: ~ 100 μm for minimum deformation and 
fabrication  possibility 
Assumption Target cells will follow velocity vector or stream/path line 
Boundary conditions Velocity inlet, pressure outlet (atmosphere pressure) 
Material Water 
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The HFRD2s used two sections to control the flow rate and velocity in each section by 
manipulating the outlet flow rates. The first section had the variable depth main channel – 
with the depth decreasing from 130 to 30 µm. The width of the HFRD2 was reduced to 1 mm 
to reduce the inlet velocity and decrease the maximum pressure and collision velocity of the 
target cells. The 30 µm depth in the second section was to maximize the recovery rate. A 
schematic of the HFRD2 is shown in Figure 3.23.  
 
 
 
 
Figure 3.23 Schematic drawing of the HFRD2 
 
 
 
2 mm 
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(a)  
 
(b)  
  
(c) 
Lt: Total length of main channel W: Width of main channel (W=1 mm) 
L1: Length of 130 µm depth main channel S: Width of side channel (S= 100 µm) 
Lv: Length of variable depth section c: Depth of main channel at L2 (c=30 µm) 
L2: Length of 30 µm depth main channel h: Initial depth of  the variable depth section 
g: Depth of side channel (g= 5 µm)  (h = 100 µm) 
Figure 3.24 Dimensions of the first section for the HFRD2: (a) top view of the channels, (b) 
side view of channels, and (c) front view of the channels 
 
Table 3.8 Cases of the first section on HFRD2 (g= 5µm) 
Cases L1 [mm] Lv [mm] L2 [mm] Lt [mm] 
G1 10 6 3 23 
G2 5 6 8 23 
G3 5 9 12 30 
G4 10 10 0 24 
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Four cases were simulated for the first section of the HFRD2. The schematic and the 
dimensions for each case are shown in Figure 3.24 and Table 3.8 respectively. The axial 
mean velocities versus the distance from the inlet to outlet in the first section are shown in 
Figure 3.25. The inlet velocity was 96.2 mm/s to obtain the target flow rate of 7.5 mL/min. 
Cases G1 and G2 show an increasing velocity at the end of Lv region because the decreasing 
ratio of main channel depth is too large compare to flow rate capacity of the side channel at 
that region. Since the axial velocity should be minimized for the maximum duration time in 
the second section, case G3 can be an option for the first section dimensions. However, case 
G3 may produce a backflow from the end region of the first section reservoir to the main 
channel or to the second section due to too low a flow rate with suction at the main outlet to 
control the flow rate. It is also possible to show no flow at the end of second section if there 
is no flow rate control at the main outlet or if there is reverse pressure gradient between the 
reservoir and the main channel in the second section.  Case G4 has a higher axial mean 
velocity than case G3 at the end region, but the mean axial velocity will be reduced in the 
second section. The total length (L1+Lv+L2) is shorter than case G3 and the slope of the Lv 
region is lower than case G3, so case G4 was chosen for the first section design. Simulation 
was individually performed for the first section and second section due to a hardware 
limitation. 
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Figure 3.25 Axial mean velocities of the first section cases on HFRD2 
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The second section was also simulated to identify the best dimension. The second section 
had a constant depth main channel (c= 30 µm) and different length channels for each case. 
The schematic of the second section is shown in Figure 3.26 and dimensions for each case 
are shown in Table 3.9. Multiple inlet velocities for cases were simulated to check the effect. 
The results of the simulations of the second channel are shown in Figure 3.27. The slopes of 
the axial velocities were not dependent on the length (Ls) but rely on the inlet velocities. 
 
(a) 
 
(b) 
 
(c) 
Figure 3.26 Dimensions of the second section for HFRD2: (a) top view of the channels, (b) 
side view of channels, and (c) front view of the channels 
 
Table 3.9 Cases of the second section on HFRD2 (g= 5µm) 
Cases Ls [mm] 
S1 12.5 
S2 18 
S3 25 
S4 33 
 
Ls: Total length of side channel W: Width of main channel (W=1 mm) 
c: Depth of main channel (c=30 µm) S: Width of side channel (S= 100 µm) 
g: Depth of side channel (g= 5 µm)  
 
Ls 
Y 
X 
Z 
X 
 
S W 
g 
c 
87 
 
 
 
 
Figure 3.27 Axial mean velocities of the second section cases for the HFRD2 with multiple 
inlet velocities 
 
Based on the multiple simulations for the first and second sections, cases G4 and S4 were chosen 
for prototype dimensions. The results of the total channel (first section + second section) 
simulation is shown in Figure 3.28. The axial mean velocity of the case HFRD2 which is 
combined with case G4 and S4 is shown in Figure 3.28. It has less than 1 mm/s velocity after 34 
mm away from the inlet with the 96 mm/s inlet velocity which gives the target inlet flow rate, 7.5 
mL/min. However, the simulation was based on water only and reservoir was not considered due 
to limits on the mesh element number. Moreover, it was assumed to be a Newtonian fluid. Axial 
accumulation of erythrocytes may help to keep the target cells in the main channel because the 
erythrocytes may occupy the highest velocity zone in the channel (near the side channel and core 
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of the main channel) but this phenomenon was not considered [11-13]. Multiphase simulation 
with whole blood components may give more information. 
 
 
Figure 3.28 Axial mean velocities of the total channel (first section G4 + second section S4) for 
the HFRD2 
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 High Flow Rate Device Version Three (HFRD3) 3.4.4.
A schematic of the third high flow rate device (HFRD3) is shown in Figure 3.29. HFRD3 
has two sections to control flow rate and velocity in each section by manipulating the outlet 
flow rates to match the simulation result if necessary. The first section has a variable depth 
main channel - the depth decreases from 130 to 30 μm which is purple channel in Figure 3.29. 
The selection of the 130 μm depth and 5 mm width for the main channel were to reduce the 
highest axial velocity, lateral velocity, and the pressure by reducing the inlet velocity. The 
simulation conditions are the same as case HFRD2 and are shown in Table 3.7. 
 
 
 
Figure 3.29 Schematic drawing of the high flow rate device version three (HFRD3) 
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The enlarged width of the main channel in the Lv, which has decreasing depth, will help 
to reduce the length of Lv without increasing the velocity. The reduction of the cross-
sectional area in Lv by decreasing the depth was recovered by increasing width. The wider 
main channel in the second section with a 30 μm deep main channel will also help to 
decrease the velocity to maximize cell capture. The detailed dimensions of the first section 
and each case are shown in Figure 3.30 and Table 3.10. 
 
 
Figure 3.30 Dimensions of the first section for the HFRD3 
 
 
Table 3.10 Cases of the first section on HFRD3 (g= 5µm) 
 
 
 
 
 
 
Cases L1 Lv L2 Wo 
P1 20 6 3 5 
P2 10 10 0 10 
P3 20 10 0 10 
P4 20 10 4 10 
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The axial mean velocities as a function of location in the first section are shown in Figure 
3.31.The inlet velocity was 19.24 mm/s, which is 20 % of cases HFRD2 (V= 96.2 mm/s) for 
7.5 mL/min. The outlet velocity of case P2 was higher than the initial velocity due to the too 
large a reduction in the main channel depth. Based on the outlet mean axial velocity results, 
case P2 is not a good option to minimize the inlet velocity at the second section entrance. 
The other cases (P1, P3, and P4) were suitable options for the first section channel based on 
the mean axial velocity results.  
 
 
 
Figure 3.31 Axial mean velocities of the first section cases for HFRD3 
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It is very important to investigate the collision velocity or prospective exclusion velocity 
(the lateral velocity of the target cells at the moment of contact or exclusions) to avoid target 
cell loss. The Figure 3.32 shows the cross-sectional view of the side and main channel. The 
path of the lateral velocity (collision velocity, or exclusion velocity) is shown in Figure 3.32. 
The circle in the main channel indicates the target cell. The exclusion path line for the lateral 
velocity was the x-direction line which was 5 μm from the side channel and 5 μm from the 
top surface. The path line: (X, Y, Z) = (X, 5 μm, 5 μm) from the reference point in Figure 
3.32. The lateral velocities for cases P1~P4 are shown in Figure 3.33. Cases P2 and P3 had 
lower lateral velocities compared the other cases. Therefore, P3 is a good option for the first 
section design since P2 is not acceptable due to the high axial mean velocity at the end. 
 
  
Figure 3.32 Collision path line (X = 5 µm and Y = 5 µm) and reference point in a cross 
sectional view of main and side channels  
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Figure 3.33 Lateral velocities on the collision path for each case of HFRD3 
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The second section was designed as 30 μm depth of constant main channel with 5 μm 
depth of side channel which is similar with S4 in Figure 3.26 except the width of main 
channel. The width of the main channel of the second section for the HFRD3 was 10 mm. 
The schematic and dimensions are showing in Figure 3.34. The length of the side channel 
was determined as a maximum length. It was limited to 33 mm due to the size restrictions of 
the brass mold insert used. The mean axial velocity of the second section is showing in 
Figure 3.35. The mean axial velocity at the end was less than 2 mm/s which is lower than the 
target velocity.  A longer second section would give a lower velocity with a larger mold 
insert. 
 
 
(a) 
 
(b) 
 
(c) 
Ls: Total length of side channel (Ls=33 mm) W: Width of main channel (W=10 mm) 
c: Depth of main channel (c=30 µm) S: Width of side channel (S= 100 µm) 
g: Depth of side channel (g= 5 µm)  
Figure 3.34 Dimensions of the second section for HFRD3: (a) top view of the channels, (b) 
side view of channels, and (c) front view of the channels 
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Figure 3.35 Axial mean velocity of the second section of the HFRD3 
 
The design of HFRD3 was completed based on the axial velocity and the lateral velocity. 
The first section was chosen as case P3 and the length of the second section was 33 mm. 
Since the minimum collision velocity of the target cell on the 5 μm depth of side channel to 
avoid the target cell loss is still unknown, designing minimum lateral velocity will give 
maximum flow rate device. The complete device could not be simulated because the required 
number of mesh elements was not acceptable for a conventional computer. High performance 
computing may solve the hardware limitations and time issues for the simulation of the 
complete device. Subsequent target cell capture experiments will verify the simulation results. 
Figure 3.36 shows the mean axial velocity for the total device (the first section and the 
second section) and Figure 3.36 shows the lateral velocities of the first and second section 
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channel. The pathlines of the first section and second section are shown in Figure 3.38 and 
Figure 3.39. 
Figure 3.36 Axial Velocities of the first and second section channel for HFRD3 
 
 
Figure 3.37 Lateral velocities of the first and second section channel for HFRD3  
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Figure 3.38 Pathlines of the first section for HFRD3 
 
 
 
 
Figure 3.39 Pathlines of the second section for HFRD3  
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3.5 Analytical Solution of Side Velocity  
The average side velocity can be briefly determined by the design target and constraints 
with channel geometry. Since the lateral velocity or collision/contact velocity should not 
exceed the exclusion velocity of the target cell to avoid target cell loss, the side velocity is 
important. Table 3.11 shows the design goal and constraint: target flow rate, target outlet 
velocity, depth of main channel at the main outlet, depth of side channel. The simplified 
channel geometry is shown in Figure 3.40. Assume that two side channels are connected to 
the main channel having one inlet, two side outlets, and one main outlet. The continuity 
equation is  
Q=A•V   (1) 
The Q is flow rate, A is cross sectional area, and V is mean velocity. The conservation of 
mass flow rate for an incompressible fluid yields  
Qin=2Qs+Qo   (2) 
The Qin is the inlet flow rate, the Qs is the outlet flow rate at side channel, and the Qo is the 
outlet flow rate of the main channel. Based on the Table 3.11 and the two equations, 
continuity and conservation of mass flow rate for an incompressible fluid, the side velocity 
(Vs) is a function of the main channel outlet width (Wo) and the length of the side channel 
(Ls):  
   
           
       
 (3) 
Table 3.11 Constraints of high flow rate device with constant depth main channel 
Inlet Flow Rate 
(Qin) 
Outlet Velocity of 
the Main Channel 
Depth of Main Channel 
at the Main Outlet 
Depth of Side Channel 
0.75 mL/min < 2 mm/s 30 μm 5 μm 
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Figure 3.40 Simplified design of HFRD; Qin, Qs, and Qo indicate main inlet flow rate, side 
outlet flow rate, and main outlet flow rate respectively. (Ls: length of side channel, Wo: 
width of main outlet) 
  
From Equation (3), a plot of the mean side velocities (Vs) is shown in Figure 3.41 based 
on the main channel outlet width (Wo) and the side channel length (Ls). Each line in Figure 
3.41 indicates a different length of the side channel. For example, Vs (Ls=70 mm) is the case 
of a 70 mm of the side channel length. Applying this to HFRD3 with a 10 mm outlet width 
and 60 mm length of side channel, the average side velocity can be approximated as 20 mm/s. 
This also indicates the the maximum lateral velocity for that case may be higher than 20 
mm/s. To get a lower maximum lateral velocity (Vs), a longer side channel or wider exit is 
required. It can be useful for estimating the ideal side velocity. 
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Figure 3.41 Graph of the side velocity as a function of main channel outlet and side channel 
length 
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3.6 Conclusions 
 A new concept for a target cell capture device using antigen/antibody binding was 
introduced and realized. Side channels were combined with a main channel. The depth of the 
side channels was determined as 5 µm based on the demonstration and simulation results. 
Depth of the main channel in the second section was 30 µm for the maximal encounter rate. 
A drilling guide was introduced for the inlet reservoir to minimize target cell loss due to 
misalignment. From the multiple simulation results and demonstration, inlet velocities were 
reduced by enlarging the inlet cross-sectional area. Lateral velocities, or the collision velocity, 
near the side channel were minimized to avoid target cell loss. Mean axial velocities in the 
second section were minimized for maximal target cell recovery rate. An analytical solution 
of the side velocity was established. However, the simulation was based on the Newtonian 
fluid and assumed the target cells will follow the path line. Moreover, blood rheology was 
not considered for this simulation. Experiments with whole blood are needed to verify the 
simulation results. 
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CHAPTER 4: EXPERIMENTS 
 
4.1 Introduction 
Target cell capture experiments were grouped in three steps. The first step was device 
preparation, including device design and fabrication, surface functionalization and antibody 
immobilization, sealing, and capillary connection.  The second was sample preparation 
including obtaining single or small numbers of CTC. The third was CTC capture and 
identification including target cell capture from human blood and investigation of the capture 
location. Detailed processes and new protocols are introduced in this chapter. Device design 
was finalized from simulation results, Chapter 3. The device was fabricated on polymethyl 
methacrylate (PMMA) using hot embossing with a micro milled brass mold insert because it 
is a relatively fast, simple, and inexpensive process compare to the LIGA process. Sealing of 
the high flow rate device was a challenge due to its very low aspect ratio and large thickness 
variation of the PMMA device. A new sealing protocol was established that overcame the 
sealing issues. Surface functionalization and antibody immobilization were accomplished and 
verified using a second antibody. New sample preparation methods were introduced and 
applied for rare target cell capture experiments. The results for CTC capture with the capture 
location in the device are presented. 
 
4.2 Fabrication of a Polymer Micro Chip 
Poly(methyl methacrylate), PMMA, was used for the cell capture device because the 
PMMA is an inexpensive and biocompatible thermoplastic material. Therefore, it is 
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applicable for disposable devices and clinical use. Moreover, fabrication of the PMMA 
device is a relatively fast and easy process compared to silicon or other hard material 
fabrication. PMMA or polymer devices can be fabricated using LIGA (or LIGA-like), micro 
milled mold inserts, polymer direct milling, or laser ablation. Polymer direct milling and 
laser fabrication processes are not suitable for mass production of cell capture devices due to 
the relatively slow process and resulting rough side walls. The LIGA (or LIGA-like) process 
can give precise dimensional control of the device, but it is a relatively complicated, multi 
step process, to achieve a mold insert. Unlike other processes, micro milling technology is 
much simpler and faster and it is also suitable for a multi height or level mold insert. Once a 
mold insert is fabricated, PMMA devices can be continuously fabricated using hot embossing 
or injection molding. Therefore, hot embossing or injection molding with a micro milled 
mold insert was very acceptable method for mass production and for the fabrication of the 
cell capture device. PC (Polycarbonate) and Cyclic Olefin Copolymer (COC) can also be 
used for the cell capture device, but both are more difficult to functionalize. 
4.2.1 AutoCAD Drawing and PMMA Device Fabrication 
AutoCAD v2008 (AutoDesk, Inc., San Rafael, CA, USA) was used for the mold insert 
design. The height of each layer was used as the name for each layer, for easy identification. 
Therefore, the layer names in AutoCAD indicate different height structures on the mold 
insert. Since brass, an alloy of copper and zinc, was used for micro milling the mold insert, 
the aspect ratio cannot be more than five. Multiple designs or duplicated structures in a mold 
insert were used to reduce the number of mold inserts or the hot embossing (or injection 
molding) processes. Each design or structure on a mold insert was isolated using tall (500 μm) 
and wide (700 μm) rectangular structures, shown in Figure 4.1. The surrounding outline 
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structures also aided in filling of the polymer during hot embossing and enabled clean cutting 
of each device from the substrate after hot embossing. The rectangular outline structures 
should be separated to extract trapped air in the outline during hot embossing. The trapped air 
prevents the complete filling of the mold with polymer. Free or empty area around the each 
device pattern was occupied by dummy structures. The dummy structures will help to 
achieve a straight long channel during hot embossing and also reduce trapping of air during 
thermal bonding.  
The polyline option in AutoCAD was used to test the connectivity of all of the lines and 
to be compatible with the operating software for the micro-milling machine. Based on the 
AutoCAD drawing, the brass mold insert was fabricated using a micro-milling machine 
(MMP, KERN Micro- und Feinwerktechnik GmbH & Co. KG, Eschenlohe, Germany). For 
micro-milling, a 1 mm diameter bit rotating at 30000 rpm and a 350 mm/min feed rate was 
used. For finishing, a 200 μm diameter diamond tool was used while turning at 40000 rpm 
with a feed rate of 150 mm/min.  
For the mold insert labeling, “Name-Dimension-Date” was used. For example TP-
020100-0107, „TP‟ means Taehyun Park`s mold insert, the „020100‟ indicates a depth and 
width of channel (20 μm depth and 100 μm width), and the „0107‟ tell the fabrication date of 
the mold insert (Jan/2007).  
From the brass mold insert, the PMMA cell capture devices were hot embossed using a 
Jenoptik HEX 02 (Jena, Germany) system at the Center for Advanced Microstructures and 
Devices (CAMD) at LSU. The PMMA was MC grade Plexiglas (Champion Industrial 
Plastics, Baton Rouge, LA, USA) and the thickness was 1/16 inch. A schematic of a hot 
embossed PMMA device is shown in Figure 4.1 (b). 
106 
 
 
Hot embossed polymer devices were cut along a cutting guide groove, which was defined 
by the outline structures on the mold insert, by table saw (Microlux, Japan.) The cutting 
guide grooves, 700 μm wide and 500 μm deep, gave clean cut edges on the device and 
minimized the variation of contact area between the actual device dimensions and the initial 
design which was used for contact area calculations. 
 
 
   (a)       (b) 
Figure 4.1 Illustration of (a) brass mold insert and (b) hot embossed PMMA device 
 
4.2.2 Connection Issues for the Microfluidic Chip 
Connections from the macro capillary tubes to the micro channels are very important for 
rare cell capture experiments because cells can be trapped or lost through improper 
connection or non-smooth geometric features. The device and connector should minimize the 
recirculation volume for minimum cell trapping or cell loss during target cell transportation. 
Moreover, the working solution should flow smoothly from the capillary tube to the micro 
channel through a reservoir area in the microchip. However, there is dead volume along the 
flow path and the recirculation usually occurs in the dead volumes and causes cell loss or 
trapping. Elimination of the dead volumes would be the best solution but it is still a challenge 
Dummy structures 
Outline structure 
Reservoir 
Cutting guide 
groove 
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since it is a product of the size change, from macro to micro, and geometric profile 
differences, such as from circular to rectangular. Inlet ports to connect with the capillary 
tubes were drilled. The size of the drill bit was similar with the outer diameter of the capillary 
to reduce the dead volume and for smooth flow of the working solution. Otherwise, the gap 
between the outer surface of the capillary and inner surface of the drilled hole will create 
dead volume and recirculation.  
The drilled hole should be clean and should not have burrs to minimize cell trapping by 
the rough surface or burrs on the edge of the drilled holes. The maximum rotation speed 
(5000 rpm) on the drilling machine (Microlux, Japan) was used to minimize burr formation. 
The location of the drill center was also important because the mismatch between the center 
of the reservoir and core of the capillary will create significant dead volume and in the worst 
case may block the sample flow. Figure 4.2 shows the mismatch and burrs between the 
centers and the improved design to reduce the mismatch. Drilling positions for the Figure 4.2 
(a) and (b) were determined by naked eye without a drill guide hole which was explained in 
Section 3.3.2. To minimize cell trapping at the reservoir due to the sudden contraction or at 
the edge of the drilled hole due to burrs, the inlet reservoir was deeper than the channel 
entrance area. The reservoir design is showing in Figure 4.2 (c). Tall burrs on the edge of the 
drilled hole will block the target cell if the reservoir is not deep enough.  
The cleaving of the capillary tube end was also important, especially for fused silica 
capillaries. Improper end cleaving of the capillary will block the sample flow or trap the 
target cells. Cells tend to stick to the unclean end on the capillary. Examples of the capillary 
end cleaving are shown in Figure 4.3. 
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(a) (b) 
  
(c) (d) 
Figure 4.2 Cross-sectional view of the reservoir showing the mismatched centers and 
improved design; (a) The mismatch between the silica fused capillary center and the 
reservoir center was over 200 μm with huge burrs around the drilled hole which was much 
larger than the inserted capillary. (b) The mismatch between the polymer capillary center and 
the reservoir center was approximately 160 μm, and the gap between the outside of the 
capillary and the inner surface of the drilled hole are relatively small. The burrs on the edge 
of the hole were reduced with high rpm (>3000 rpm.) (c) Red cylindrical structure at the 
reservoir center on the mold insert indicates the drill guide structure. (d) Center drilled hole 
using the improved design has less than 10 μm mismatch. 
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                 (a)                     (b) 
Figure 4.3 Example of capillary end cleaving: (a) improper end cleaving and (b) fine end 
cleaving 
 
Once the device was cut and drilled for capillary connection, a cleaning process was 
carefully done to eliminate residual particles in the channel or burrs on the reservoir which 
can block the flow of cells. Cleaning was done using ultrasound (Branson, Danbury, CT, 
USA) with 90% demonized water (DI water) mixed with 10% Isopropyl alcohol (IPA). 
During the ultrasonication, the temperature of the solution should not be warmed to avoid 
deformation of melting of the PMMA device. Sonication with isopropyl alcohol mixed with 
DI water can remove sharp burrs and particles on the device. However, some of the particles 
in the channel may not be removed. For complete removal of these particles, high pressure 
nitrogen gas (over 60 psi) was used. After sonication and nitrogen gas cleaning, the polymer 
device was rinsed with DI water. After all of the cleaning steps, the channels were carefully 
examined under a microscope and stored in a 70 ~ 85 °C oven (VWR 1620, West Chester, 
PA, USA) for overnight for dehydration and annealing. 
4.3 Polymer Modification and Functionalization 
Antibody immobilization on polymer surfaces is one of the main processes for cell 
capture. Pristine PMMA (-COOCH3) can be modified to a carboxyl group (-COOH) 
modified PMMA surface using UV modification. The carboxylated group can be amine 
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functionalized (-NH2) by adding ethylenediamine with EDC (1-Ethyl-3-(3-
dimethylaminopropyl)-Carbodiimide) [1-4]. Finally, the amine functionalized surface can be 
replaced by an antibody immobilized surface using EDC coupling with antibody (AB) [5, 6]. 
The illustration in Figure 4.4 shows the chemical structure changes on the polymer surface 
during the modification and functionalization process.  
 
 
 
 
 
 
 
 
 
Figure 4.4 PMMA modification and functionalization process [1]  
 
 UV Modification of the Polymer Surfaces 4.3.1
Pristine PMMA was modified using an ultraviolet (UV) exposure station (ABM, Inc., 
San Jose, CA). The wave length of the UV station was 254 nm and its UV intensity was 
approximately 15 mW/cm
2
. 
Surface modification using UV exposure and isopropyl alcohol (IPA) rinsing process 
changes the properties of the PMMA surface from hydrophobic to hydrophilic. Hot 
embossed PMMA showed approximately a 92 degree water contact angle; after UV exposure 
(5 ~ 20 min) the average of water contact angle was between 90 ~ 100. Further IPA rinsing 
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dropped the average water contact angle to 70 ~ 75. The water contact angle of PMMA 
shows a different result from previous studies which used pristine PMMA [1-3]. The PMMA 
was hot embossed PMMA and roughness was changed. MC grade PMMA from Plexiglas 
(Altuglas Int`l., Philadelphia, PA) and Cyro Acrylite FF grade PMMA (Evonik Cyro, 
Parsippany, NJ) were used. The water contact angle was measured before UV modification, 
after UV modification, and after IPA rinse. This is because of surface roughness changes 
from the hot embossing using a micro milled brass mold insert, or different type/grade of 
PMMA. However, the water contact angle after the IPA rinse was not much different from 
the previous study using pristine PMMA [1-3]. Figure 4.5 shows the change of the water 
contact angle before and after the IPA rinse as a function of the UV exposure time. Appendix 
B shows the detailed data on the water contact angle experiments.  
For a 15 mW/cm
2
 intensity of the 254 nm wave length UV light, the exposure time was 
chosen as 6~8 minutes to avoid surface damage. However, the surface damage depends on 
the PMMA type (manufacture, grade, fabrication) and process (hot embossed or pristine 
PMMA). For example, the CQ PMMA (Vista Optics, Widnes Cheshire, UK) did not show 
the surface damage under the same conditions with other PMMA.  
 
Table 4.1 Protocol of UV Modification for Carboxyl Group (-COOH) Modified PMMA 
Steps Processes 
1 Expose the cleaned PMMA under UV light for 8 min.  
(Exposure time depends on UV intensity and PMMA type) 
2 Wait until the exposed PMMA cool down. 
3 IPA rinse and DI water rinse. 
4 Nitrogen gas dry. 
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(a) 
 
(b) 
Figure 4.5 Water contact angle after UV exposure: (a) before IPA rinse (b) after IPA rinse 
(The middle value on the vertical line indicates the average of the water contact angle, and 
upper and lower little horizontal bars indicate the maximum and minimum value of water 
contact angle at each exposure time.) 
Hot Embossed 
PMMA 
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Figure 4.6 Surface damage of the PMMA depends on UV exposure time; UV exposure time 
shown under the each pictures. 
 
Figure 4.6 shows the physically damaged PMMA surface based on the different exposure 
times under 15mW/cm
2
 UV.  After 10 minutes of UV exposure the PMMA surface was clean 
but at 30 minutes of exposure the PMMA surface was a milky color. For a 60 minute 
exposure, the PMMA surface was totally damaged. Additionally, the intensity of the UV can 
be changed due to the UV lamp condition and the exposure time should be changed based on 
the UV intensity. For a 20 mW/cm
2
 intensity of the 254 nm wave length, a 200 second 
exposure time was selected. 
 
4.4 Thermoplastic Fusion Bonding 
Sealing of the PMMA device is an important process. The device requires a strong bond 
without contamination and with minimal deformation of the geometry. It should be strong 
enough to avoid device rupture under high pressures in the channels. Contamination can be 
an issue for biological applications. Deformation will also lead to uncertain flow behavior. 
There are many bonding techniques for polymer micro devices [7-16]. However, 
thermoplastic fusion bonding or thermal bonding is the recommended method for the cell 
capture device because it can provide a strong bond without any contamination. The simplest 
polymer sealing method is using a glue or adhesive, such as an epoxy or acrylate. However, 
60 minutes 30 minutes 10 minutes 
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it may cause several problems such as channel clogging by extra glue or solution leaking into 
any gaps between the parts and the adhesive layer. Moreover, contamination by the adhesive 
or glue layer can be a problem for biological applications. Laminated adhesive film may be 
used for polymer sealing [12, 13]. However, it may also have a potential contamination issue 
and limited material uses. Solvent bonding is a relatively easy method, but it requires 
complete removal of the solvent and is not recommended for functionalized devices [16]. 
Welding using either laser or ultrasound is a complicated process and requires special tools 
and specific geometries at the interface for best results. Therefore, thermal bonding was 
selected and tried for all polymer cell capture device sealing. 
4.4.1 Glass Transition Temperature of a Polymer 
The glass transition temperature (Tg) of a polymer is very important for thermal bonding 
because the three basic parameters (temperature, pressure, and time) of thermal bonding are 
dependent on the glass transition temperature of the polymer.  
Polymers are viscoelastic materials which have elastic and viscous behavior. There are 
five regions as a function of temperature for linear amorphous polymers, shown in Figure 4.7. 
The first region is the glassy region where brittle behavior is common – this is true for 
PMMA at room temperature. In this region the Young`s modulus of the polymer is constant 
up to the just below of the glass transition temperature. The second region is the glass 
transition region (leathery behavior.) In this region the polymer will be affected even by a 
few degrees temperature change. 
The glass transition temperature is usually at the part of the maximum rate of turndown 
of the modulus or at the temperature where the coefficient of thermal expansion (CTE) 
exhibits a discontinuity. In the glass transition region the number of chain atoms in motion 
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are 10 ~ 50 (40 for PMMA) while only 1 ~ 4 chain atoms are in motion below the glass 
transition temperature [17, 18]. A simple explanation of the glass transition is that the 
polymer is between glassy and rubbery states or a sharp drop of Young`s modulus, as shown 
in Figure 4.7 [19]. 
 The third region is a rubbery plateau region where an elastomer can be stretched more 
than one hundred percent. For semi-crystalline polymers, the polymer behavior will follow 
the dashed line after the second region in Figure 4.7. The fourth region is a rubbery flow 
Figure 4.7 Illustration of viscoelastic behavior (five regions) for a linear amorphous 
polymer. Dashed line is for crystalinity effect and the dotted line is for cross-linking 
effect [19]. 
Tg 
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region which shows both rubber elasticity for a short time scale experiments and flow 
behavior for long time scale experiments. In this region, there is no cross-linking. The last 
region of the linear amorphous polymer as temperature increases is the liquid flow region in 
which the polymer flows readily.  
The glass transition can be experimentally found by measuring the thermodynamic, 
physical, mechanical, or electrical properties with temperature changes. The methods for 
measuring glass transition temperature are based on measuring properties, such as the 
volume, modulus, or dielectric loss. There are three main theories describing the glass 
transition temperature of polymer as a molecular level [20, 21]; free-volume theory, kinetic 
theory, and thermodynamic theory. The free-volume theory starts from existing voids in the 
bulk states. The voids, vacant or empty space between molecules, are called free volume and 
depend on the pressure. A pressure increase causes both the total volume and the free volume 
to decrease. The deceasing volume increases Tg. The pressure coefficient of the glass 
transition temperature, dTg/dP, for PMMA is 0.02 ~ 0.023 K/atm at Tg = 105°C [22]. The 
kinetic theory of glass transition implies that the change of the glass transition temperature is 
based on a time frame; the glass transition temperature of a polymer shifts 6 ~ 7 °C per 
decade. The thermodynamic theory involves the variation of Tg with the molecular weight 
and cross-link density, dilution content, and other variables. The glass transition temperature 
is related to the cross-link density, molecular weight, polymerization or copolymerization, 
time, crystallinity, chemical structure, tacticity, and pressure. 
The polymer properties at or near the glass transition temperature are the main concern 
for thermal bonding. At or near Tg or in the glass transition region in Figure 4.7, small 
temperature increases cause large decreases in the Young`s modulus of the polymer 
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compared to the glassy state [23]. The deceased Young`s modulus increases the deformation 
during the thermal bonding process. Therefore, precise temperature control is needed for 
minimum deformation during thermal bonding.  
The operating pressure during thermal bonding will also affect the deformation. The time 
variable for thermal bonding may not effect much more than the other parameters, 
temperature and pressure. After an hour of thermal bonding operation, the thermal bonding 
result (sealing force and deformation) did not change significantly. Therefore, control of 
temperature and pressure is the key to achieving a successful thermal bonding result which 
means strong bonds with small deformation. Successful thermoplastic fusion bonding 
requires not only the optimal condition of the temperature and pressure but also requires the 
optimal condition of the polymer device, flat and clean bonding surfaces. The polymer 
device needs to be checked for flatness since the device can be deformed by hot embossing 
or UV modification. Additionally, the polymer needs to be dehydrated to avoid water vapor 
effects during thermal bonding. The protocol of thermoplastic fusion bonding is shown in 
Appendix E.  
Thermoplastic fusion bonding results are shown in Figure 4.8 and the conditions for each 
case in Figure 4.8 are shown in Table 4.2. Thermal bonding can be performed for multi 
stacked devices for a modular system. Figure 4.9 shows the multi stack thermal bonding 
which was accomplished in one thermal bonding process. It is also possible to stack thermal 
bond multiple modules from previously thermal bonded individual modular devices or chips. 
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Figure 4.8 Cross-sectional view of thermoplastic fusion bonding results for narrow micro 
channels, 100 μm width and 20 μm depth for (a) and (b), and large dummy structures, 
1000 μm width and 100 μm depth for (c) and (d). (a) and (c) show large deformation and 
(b) and (d) show acceptable deformation. (e) and (f) show the top view of food color 
filled micro channel. Conditions for each case are shown in below table. 
 
Table 4.2 Conditions for each case in Figure 4.8 
Cases (a) (b) (c) (d) 
Temperature 110°C 105°C Over 120°C 110°C 
Pressure 20 psi 10 psi 20 psi 20 psi 
time 90 min 90 min 30 min 30 min 
 
(a) (b) 
(c) (d) 
(e) (f) 
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Thermoplastic fusion bonding requires the device surfaces to be flat. Parameters such as 
temperature, pressure, and time must be precisely controlled to achieve minimum 
deformation and strong bonding. Current thermal bonding techniques use commercial ovens 
and paper clips, custom-made spring jig, or weights to apply pressure [24]. However, the 
precise pressure control is not easy with current methods and the temperature also depends 
on the location of the device in the oven. Another alternative method for thermoplastic fusion 
bonding is using a boiling liquid in a pressure cooker. The advantage of thermal bonding 
using a pressure cooker is that the boiling temperature of the fluid is dependent on the vapor 
pressure and its evaporation pressure can be used for thermal bonding. Moreover, precise 
control of the parameters can be achieved simply.  
4.4.2 Thermal bonding Using a Pressure Cooker 
Figure 4.10 shows the basic concept and the modification to the pressure cooker for 
thermal bonding. A commercial pressure cooker (Philippe Richard 8-Qt, China) was used for 
polymer thermal bonding. The maximum operating condition of the pressure cooker was 
higher than 15 psi pressure; the operating pressure for the thermal bonding application was 
Figure 4.9 Thermoplastic fusion bonding of a multi-stacked device: thermal bonding of 
five chips in the one bonding process (arrows indicate 20 μm depth of microchannels.) 
Micro channels in each chip 
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under 10 psi. Therefore, using the commercial pressure cooker for thermal bonding did not 
have any safety issues. The pressure cooker was connected to a pressure relief valve 
(McMaster-Carr 48935K25, Cleveland, OH, USA) and pressure gage (McMaster-Carr 
4088K29, Cleveland, OH, USA) through a pressure tube to control a pressure which 
governed the boiling temperature. Another tube, a vent tube, was connected to the polymer 
Pressure relief 
valve 
Pressure gage 
Vacuum 
probe 
Polymer devices 
Vent 
tube 
Vacuum 
probe 
Polymer 
vacuum bag 
Pressure tube 
Vent tube 
Boling water 
Burner 
Vapor pressure 
Pressure gage 
Pressure relief valve 
Pressure cooker 
Pressure tube 
Vent tube 
(a) (b) 
 
(c) 
 
(d) 
 
(e) 
 Figure 4.10 Thermoplastic fusion bonding using a pressure cooker: (a) schematic 
representation of the pressure cooker modified for thermal bonding, (b) tube connections to 
the system, (c) pressure control unit (enlarged picture of white dashed rectangular line in 
(b)), (d) inner tube connection and vacuum probe, and (e) Vacuum polymer bag unit 
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vacuum bag (Foodsaver T150-00011-002, Sunbeam Products, Neosho, MO, USA) using a 
vacuum probe (Torr 353444, Torr Technologies, Inc., Auburn, WA, USA). The polymer 
devices were placed in the plastic bags and sealed using a vacuum sealer (Foodsaver V2830, 
Sunbeam Products, Neosho, MO, USA). The other end of the vent tube was opened to the 
outside air. All tubes which were connected to the pressure cooker were sealed. The vapor 
pressure in the pressure cooker compresses the polymer bag in the boiling solution. The 
operating pressure was 3 psi, generating a temperature of 105°C for PMMA thermal bonding. 
The operating pressure was not the same as the actual thermal bonding pressure which was 
the pressure at the contact surfaces of the device, There are non-contacting areas, such as 
channels, dummy structures, and reservoirs, between the device and the cover slip. The 
actual pressure at the thermal bonding contact area is larger than the operating pressure. An 
area ratio, the top or bottom area on the device divided by the contact area, is the 
amplification ratio of the actual pressure at the contact surface. For example, if a 3 cm by 4 
cm rectangular device with 6 cm
2
 of contact area is under 3 psi operating pressure, the actual 
thermal bonding pressure across the contact area (or the bonding area) of the device will be 6 
psi.  
Thermal bonding using the pressure cooker gives better results compared to the previous 
methods using a forced convection oven (VWR 1620, West Chester, PA, USA) because it 
gives even or homogenous temperature on the part stack surface and more precise pressure 
control. Figure 4.11 shows the results of thermoplastic fusion bonding using the pressure 
cooker. In Figure 4.11, (a) a top view of two thermally bonded chips is shown and in (b) a 
cross-sectional view of the chip. The operating condition was 3 psi which gave a 105°C 
temperature in the bath and approximately an 8 psi actual bonding pressure. Even though the 
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result of thermal bonding using the pressure cooker gives less deformation than the result 
using a conventional oven, it is still not fully operational for demanding results yet. The 
manual pressure control using the pressure relief valve needs to be replaced by a regulator for 
automatic control.  
Additionally, the pressure in the polymer device bag can be independently controlled by 
controlling the pressure at the end of the vent tube. Thermal bonding of PC using boiling DI 
water in a pressure cooker can be achieved; the boiling temperature can reach, for the PC, 
around 150°C, by increasing the pressure in the pressure cooker. The pressure in the polymer 
device bag can be controlled to obtain the required pressure by controlling the pressure via 
the vent tube. More experiments are needed to identify conditions for achieving the minimum 
deformation for the high flow rate device which has 5 ~ 10 μm depth and 1000 μm width 
channel. Additionally, a new method of characterizing the deformation information is needed. 
 
 
  
(a) (b) 
Figure 4.11 Results of thermoplastic fusion bonding using the pressure cooker: (a) top view 
of the thermally bonded chips and (b) cross-sectional view of dummy structure, 300 μm 
depth and 700 ~1000 μm width,  in the PMMA chip 
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4.5 Amine Functionalization and Antibody Immobilization on Polymer Surfaces 
Amine functionalized and antibody immobilized PMMA surfaces were achieved to fix 
the antibody on the polymer surface after UV modification and thermoplastic fusion bonding. 
The UV modified PMMA, carboxylated surface, changes to an amine functionalized surface 
(-NH2) by amine functionalization solution, ethylenediamine with EDC, 1-Ethyl-3-(3-
dimethylaminopropyl)-Carbodiimide, (Sigma, St. Louis, MO, USA) [6]. The protocol from 
amine functionalization is shown in Appendix F. The PMMA surface changes to an amine 
functionalized PMMA surface (amine terminated PMMA surface or aminated PMMA 
surface) from the carboxyl group modified PMMA. The last step is an antibody 
immobilization process to immobilize the antibodies on the PMMA surface. The EDC 
solution containing antibodies produces the antibody immobilized PMMA surface from the 
amine functionalized PMMA surface. The antibody, Anti-EpCAM-1 (Ab-1) Mouse mAb 
(VU-1D9), was obtained from EMD Biosciences, Inc (Gibbstown, NJ, USA.) Once the 
antibody immobilization was accomplished, the device could be stored at 4 °C for up to one 
month and used to capture target cells. The details of the antibody immobilization process are 
shown in Table 4.3. 
Table 4.3 Protocol of Antibody Immobilization 
1. Preparation of the antibody solution 
10 μl antibody (1 μg/μl with PBS) + 0.0016 g EDC + 190 μl PBS 
 Modified concentration method:  
a. 0.8 g EDC + 95 ml PBS solution 
b. Mix 10 μl antibody with 190 μl above solution 
2. Flow the antibody solution into the channel using the syringe pump. 
3. Incubate the antibody solution overnight at 4°C 
(Incubation can be done for 2 hours at room temperature) 
4. Flow PBS into the channel to rinse the antibody solution 
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4.6 Control Experiments 
To achieve optimal processes (UV modification, amine functionalization, and antibody 
immobiliation of the PMMA surfaces), control experiments were performed with three types 
of PMMA, multiple exposure times, and several process cases. The PMMA samples were 
1/16 inch thickness of MC grade PMMA from Plexiglas (Altuglas Int`l., Philadelphia, PA), 
1/8 inch thickness of Cyro Acrylite FF grade PMMA (Evonik Cyro, Parsippany, NJ), and 2 
mm thickness of Vistacryl CQ grade PMMA from Vista Optics (Widnes Cheshire, UK), 
shown in Table 4.4. The control experiments were done on an unsealed PMMA surface.  
To test the antibody immobilization performance, a fluorescein (FITC) conjugated 
second antibody (a fluorescein-conjugated affinipure donkey anti-mouse IgG, Jackson 
Immunoresearch Laboratories, Inc., West Grove, PA, USA) was bound to the first antibody, 
which had previously been coated on the PMMA surface using the antibody immobilization 
process, and the FITC intensity was measured by fluorescence microscope (Leica DM RXA2, 
Leica Microsystems Inc., Bannockburn, IL, USA). MCF-7 cells were captured on the first 
and second antibody-coated PMMA surfaces. However, counting the captured MCF-7 cells 
did not give any reliable information due to an inconsistent rinsing process. Moreover, 
binding sites on the first antibody for the MCF-7 cell may be occupied by the second 
antibody. The number of the remaining MCF-7 cells was random after a PBS rinse.  
 For the second antibody binding process, the FITC conjugated second antibody (4 mg/ml) 
was mixed with PBS (dilution ratio was 1:50). The solution was put on the first antibody 
immobilized PMMA surface overnight at 4°C for incubation. After antibody incubation, the 
solution was blown off using nitrogen gas, followed with a PBS rinse. Figure 4.12 shows the 
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PMMA preparation for the control experiments. Each PMMA sheet was divided into five 
different UV exposure time zones.   
Table 4.5 indicates the process steps performed for each case. For example,  for „Case 1‟ 
all steps, including UV modification, first antibody functionalization, and FITC conjugated 
second antibody functionalization, and MCF-7 cell capture with PBS rinsing were performed. 
For „Case 4‟ only the first and second antibody functionalization steps and MCF-7 cell 
capture without the UV modification process were carried out. Figure 4.13 shows the results 
of the control experiments. The exposure time of the fluorescence light on the fluorescence 
microscope was constant for all cases and the average FITC intensity was measured over a 
consistent area on each PMMA surface. The units of the FITC intensity were arbitrary. 
Table 4.4 PMMAs for control experiments 
PMMA Grades Brand Thickness 
MC Plexiglas 1/16 inch 
FF Cyro Acrylite 1/8 inch 
Vistacryl CQ Vista Optics 2 mm 
 
 
 
Figure 4.12 PMMA samples for the control experiments 
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Figure 4.13 shows that the FITC intensities for all cases were usually increased as the UV 
exposure time increased. The FITC intensity of Cases 1 and 4 with a 5 minute UV exposure 
time shows a sudden intensity increase for an unknown reason. It also shows that Cases 1, 4, 
6, and 7 have higher intensities than for all other UV exposure times. It is because these 
cases were used for the FITC conjugated second antibody immobilization. Even though the 
amine functionalization and the first antibody immobilization for Cases 6 and 7 were not 
accomplished, they still show a high FITC intensity. This is possibly due to non-specific 
binding of the second antibodies with the EDC coupling on the PMMA surface. The non-
specific binding phenomena also happen for the first antibody immobilization. It explains 
Case 4, which omitted the amine functionalization, and still shows a high intensity. Although 
Case 1, theoretically, should have the highest FITC intensity, the FITC intensity of Case 1 
was not significantly higher (or lower) than that of the Case 4. However, the graphs indicate 
background noise was also increased with greater UV dose. The Case 2, Case 3, and Case 8, 
which does not have FITC dye on the PMMA surface, point that longer exposure gives 
higher intensity. Therefore, 5 minutes UV exposure time was enough for antibody 
immobilization. To investigate the effect of longer UV exposure times, 60 minutes UV 
exposure time was also tested. The surface of the CQ PMMA was not visibly damaged from 
over 60 min UV exposure unlike the other PMMA, both the MC and FF grades, which 
required limited exposure times (8 min) to avoid surface damage.  These results are probably 
related to molecular weight. For the CTC capture, the FF and MC grades were used with 6~8 
min UV exposure because the price of MC or FF PMMA is much lower than the CQ PMMA.  
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Table 4.5 Control experiment cases based on the execution of the each process step (UV 
modification, amine functionalization, antibody immobilization, and target cell capture 
process) 
Process 
Amine 
Functionaization 
1
st
 Antibody 
FITC Conjugated  
2
nd
 Antibody 
MCF-7 Capture  
and PBS Rinse 
Case 1 x x x x 
Case 2 x x 
 
x 
Case 3 x 
  
x 
Case 4 
 
x x x 
Case 5 
 
x 
 
x 
Case 6 
  
x x 
Case 7 
  
x 
 
Case 8 
   
x 
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(a) 
Figure 4.13 FITC intensity from five UV exposure time, three different PMMA types, and 
six cases 
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(b) 
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(c) 
Figure 4.13 FITC intensity from five UV exposure time, three different PMMA types, and 
six cases 
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4.7 Sample Preparation 
Circulating tumor cell (CTC) research requires an extremely low target cell concentration 
because the frequency of the CTCs in human blood is very low, less than one cell per 
milliliter. However, it is difficult to prepare samples for rare CTC capture experiments since 
common cell or cancer research typically uses at least 10
6
 cells per milliliter sample. One 
option for preparing the rare cell samples is the dilution method. However, the dilution 
method, using a hemacytometer, cannot guarantee the cell concentration and is not 
recommended for fewer than 1000 cells per milliliter.  It is important to use an exact number 
of target cells because the impact of the wrong input number of CTCs will cause a large error. 
Another option is a commercial cell counter or fluorescence activated cell sorter.  However, 
it is not suitable for single or rare cell collection since those instruments require fluorescence 
labeling and need cell concentrations of more than 1000 cells/mL. Moreover, the 
fluorescence labeling and laser illumination stresses the cells. Protocols for the isolation of 
pure cells from colonies were introduced, but it is a complicated and lengthy process not 
suitable for microdevice applications [25, 26]. A method for counting small numbers of cells 
was introduced by Badders, et al. in 2008 [27]. However, it was not suitable for less than 
1000 cells/mL. Single cell analysis methods were introduced in previous research, but were 
focused on specific applications with a complicated device for each use [28, 29]. Preparation 
of samples for rare cell capture experiments, such as CTC capture research, cannot use 
previous methods because the number of target cells should be exact to accurately assess the 
effectiveness of very rare cell capture.  
An easy and simple protocol for collection of single or exact numbers of cells was 
developed to overcome the limitations of the previous methods. A hemacytometer or PMMA 
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cell collection chip with a silica capillary and syringe were used for collection of precise 
number of cell. A PMMA sheet was directly micro milled to fabricate the cell collection 
chips. The depth of the cell collection wells can be adjusted by using different size capillaries 
to support a cover glass to accommodate different size target cells. Figure 4.14 shows the 
PMMA cell collection chips with supporting capillaries. Figure 4.14 (a) is a single-wall cell 
collection chip and Figure 4.14 (b) is a multi-wall cell collection chip. The PMMA chip in 
the Figure 4.14 (b) reduced the cover glass bending which occurred due to the fixing of tapes 
on the sides of the cover glass, and it increased the number of cell collection chambers. 
For single cell collection, polyimide at the end of commercial capillary tubes was 
selectively removed by flaking off the polyimide coating over a 600°C flame. Cells were 
then visible in the capillary and the capillary was movable in the hemacytometer or cell 
collection chip. The other end of the capillary was connected to a syringe. Cells were injected 
into the cell collection chip at low concentrations, approximately 10
3
 ~ 10
4
 cells/mL. The 
modified capillary was inserted into the well under a microscope. Once the capillary was 
located near a target cell, the syringe was withdrawn to enable collection of the target cell in 
the capillary. The number of collected cells can be visually confirmed during the collection 
process. After collection of the desired number of target cells, the remaining cells and 
capillary surface were washed out with PBS. Moreover, the collected cells can be easily 
transferred to any desired location, such as a microdevice, cell culture chamber, or micro 
vials, for any further processing without any cell loss. 
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(a) (b) 
 
(c) (d) (e) 
Figure 4.14 PMMA cell collection chips with a pair of supporting capillaries which are 
located in a micro milled grooves to support a cover glass, polyimide removed cell collection 
capillary can be inserted under the cover glass and between the supporting capillaries. (a) 
Single wall cell collection chip, (b) multi wall cell collection chip, (c) schematic illustration 
the cell collection chip, (d) cover glass supporting capillary area, and (e) cell collecting 
capillary area. 
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Figure 4.15 shows the collection of a single MCF-7 cell using a hemacytometer and 
polyimide-coated fused-silica capillary under the microscope. The blue circles in Figure 4.15 
indicate a collected single target MCF-7 cell. The capillary was clearly visible and easily 
movable with the polyimide removed. The method for single cell sample preparation is 
applicable not only for CTC research, but any other rare cell analysis research. Figure 4.16 
shows the collection of a single human adipose-derived stem cell (hASC) using a cell 
collection chip.  
 
 
Figure 4.15 Collection of single cell using a silica capillary (OD=105 μm) and syringe (5 μl) 
in a 100 μm depth hemacytometer. 
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Figure 4.16 Single cell collection using cell collection chip; Polyimide was removed from the 
capillary (OD=190 μm), which was used to collect an human adipose-derived stem cell 
(50~100 μm diameter) in a 195 μm deep cell collection chip. The target stem cell is close to 
the capillary and drawn into the capillary. Because the collected cell in the capillary is above 
of the observation area, it is not visible in the capillary when the time was 9 seconds. 
Time = 0 seconds Time = 3 seconds 
Time = 6 seconds Time = 9 seconds 
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4.8 Target Cell Capture 
The target cells can be stained with fluorescence to distinguish them from blood cells or 
other control cells. The MCF-7 cells were stained with 4',6-diamidino-2-phenylindole (DAPI.) 
DAPI has an excitation wavelength of 359 nm of and emission wavelength of 461 nm. Figure 
4.16 shows the DAPI stained MCF-7 cells. In Figure 4.17 (b), the PMMA channel was 
coated by anti-EpCAM and the FITC conjugated second antibody. From the same location 
and same cell, different images were achieved using FITC or DAPI filters. 
 
(a) 
 
(b) 
Figure 4.17 Fluorescence stained MCF-7 cell: (a) DAPI stained MCF-7 cell in the 
microscope glass slides and (b) DAPI stained MCF-7 cell in the antibody immobilized 
PMMA channel 
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The target cells needed to be transferred into the cell capture zone, an antibody 
immobilized channel for most cases, without cell loss. Moreover, the cell flow should be 
controlled for maximum cell recovery rate. The anticipated optimum mean velocity of the 
EpCAM expressing target cells was 1 ~ 2 mm/s.  
Air bubbles were removed to avoid blockage of the cells by air bubbles. Air bubble 
formation originates from outside of the device through the capillary or it can be generated 
inside of the device due to a locally low pressure at sharp corners. Preexisting air bubbles in 
the dead volume were also a concern. For the cell capture experiments, DI water and PBS 
were degassed using a sonicator (Branson Ultrasonics Corporation, Danbury, CT, USA) for 
over 30 minutes. Trapped air in the microdevice was eliminated by alternately pushing and 
drawing with the syringe [30]. Figure 4.18 shows the removal of air under the microscope.  
The cell solution was driven using a syringe pump. The average velocity of the pressure 
driven fluid was controlled by flow rate control. Figure 4.19 shows an initial experiment of 
the MCF-7 cell capture in the microchannel (100 μm width and 20 μm depth) without the 
precise cell collection process. Target cells were stained with DAPI (or trypan blue). 
 
Figure 4.18 Elimination of air bubble by suction and pushing under the microscope 
 
136 
 
 
 
(a) 
 
(b) 
Figure 4.19 MCF-7 cell capture in the antibody immobilized microchannel: (a) DAPI and 
trypan blue stained MCF-7 Cells and (b) DAPI stained MCF-7 cells 
 
The cell solution was infused into the antibody immobilized channel. The average 
velocity of the MCF-7 cells was 2 mm/s More than 10
6
 cells in PBS were used and a PBS 
rinse at 10 mm/s followed to confirm the antigen/antibody binding and to remove any 
material that was binding non-specifically.  
A pristine PMMA channel also was used for a control cell capture experiment. No cells 
were captured in the pristine PMMA channel.  
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The rare cell capture experiments were accomplished using the rare cell collection 
method. Figure 4.20 shows the process and results. A total of 14 target cells were collected in 
the cell collection capillary. The collected cells in the cell collection capillary were delivered 
into the microchannel through the guide capillary. Before inserting the cell collection 
capillary, the air bubbles in a chamber or reservoir were removed by continuous infusion or 
suction at the inlet and outlet of the channel. Once the cell collection capillary was inserted in 
the PMMA device, the syringe pump (NE-500, New Era Pump systems, Inc., Wantagh, NY, 
USA) delivered the target cells with an average velocity of 2 mm/s.  
All 14 cells were collected, delivered, and captured very near the channel inlet. PBS rinse 
at more than 20 mm/s followed. Even though some of the cells were relocated in the channel 
during the rinsing, they did not move far away from the initial point. The relocation of the 
captured cells during rinse may due to too high shear flow or pressure in the narrow channel 
which pushes the captured cell. The MCF-7 cells barely can flow in the 20 μm channel 
because the size of the MCF-7 cells is very close to the channel size or sometimes larger. 
Even through the rare target cell capture was successful, the flow rate was much lower than 
the desired value. The flow rate for the rare cell capture was 0.24 μL/min but the desired flow 
rate is 0.75 mL/min. Therefore, a new cell capture concept or design for the high flow rate, 
0.75 mL/min, was necessary and the high flow rate design, introduced in section 3, 
developed.  
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(a) 
 
(b) 
 
(c) 
 
(d) 
Figure 4.20 Rare cell capture: (a) elimination of the trapped air bubbles, (b) inserting cell 
collection capillary, (c) cell capture without any target cell lost, and (d) captured cells in 
the channel after PBS rinse. 
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4.9 High Flow Rate Device 
High flow rate devices were designed based on the simulation results and fabricated on 
PMMA sheet using micro milled mold insert and hot embossing process. Sealing of the 
PMMA HFRDs was the key to HFRD fabrication due to the very low aspect ratio side 
channel and a variation of the substrate thickness. Sealing was performed using thermoplastic 
fusion bonding (TPFB), pressure sealing, or PMMA spin coating (PSC) technique. Pressure 
control for the TPFB was tried with paper clip, custom made spring jig, weights, a pressure 
cooker, and a local pressure control method. A forced convection oven (VWR 1620, West 
Chester, PA, USA) or hot plate also was used for temperature control. The pressure sealing 
method used two pieces of thick glass to press the HFRD and cover sheet together with paper 
clips to apply pressure. The PSC method used PMMA beads and PGMEA (propylene glycol 
monomethyl ether acetate, Sigma-Aldrich, St. Louis, MO.) The custom-made spring plunger 
assisted jig and local pressure control method are explained in Appendix A. The antibody 
was monoclonal anti-human EpCAM (Monoclonal Antibody Human EpCAM/TROP1 MAb 
(Clone 158206), Mouse IgG2B, R&D Systems, Inc., Minneapolis, MN, USA) to achieve 
high specific antigen/antibody binding. 
4.9.1 High Flow Rate Device Version One (HFRD1) 
High flow rate device version one, which had 10 µm deep side channels, was designed as 
a combination of modified case N3 (Chapter 3.4.2.2) with a longer channel (Lv = Ls = 6250 
µm) and modified case C (Chapter 3.4.2.1) with a longer channel (Lt = 6550 µm) to reduce 
velocities. The sealing of the HFRD1 was attempted using thermoplastic fusion bonding and 
a glass jig after UV modification. The forced convection oven (VWR 1620, West Chester, 
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PA, USA) was used to control the bonding temperature. Paper clips and weights were used to 
control the pressure for TPFB. The pressure cooker was also used for sealing of HFRD1. 
Figure 4.21 shows the PMMA HFRD1. There are four deformation indicators, red dotted 
rectangles, at the four corners on the device. Each deformation indicator had four chambers 
which were 10 µm or 15 µm deep and 1000 µm wide chambers to check the deformation 
information with the naked eye. Most of the results showed that the pressure distribution was 
not even. 
Figure 4.22 shows the schematic of the HFRD1 and the sealing results. The forced 
convection oven and weight were used, with a bonding temperature of 105°C, pressure was 
8.8 psi, and time was 24 hours. The first section of the HFRD1 has a collapsed area on the 
side channel even though the second section shows good bonding without the collapse of the 
side channel. This is due to the uneven pressure distribution over the whole surface of the 
HFRD1. Results for different bonding conditions are shown in Figure 4.23. The time was an 
important factor for this very low aspect ratio channel or device (1/70) because the only 
difference between Figure 4.22 (b) and Figure 4.23 (b) is the operating time. However, the 
results for the same condition were not always consistent and sealing of the very low aspect 
ratio channel/device is still a challenge. 
Figure 4.21 Thermoplastic fusion bonding using oven: deformation indicator shows uneven 
pressure distribution. 
Unbonded area 
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(a) 
 
 
(b) 
 
 
(C) 
 
Figure 4.22 High flow rate device version one: (a) Schematic drawing of HFRD1, and 
sealing results (105 °C with 8.8 psi for overnight) on (b) the first section of HFRD1 and (c) 
the second section of the HFRD1 (dark fields or arrows indicate bonded/collapsed area) 
 
Depth of Side Channel: 10 μm 
First section 
Part 
Second section 
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(a) 
 
 
(b) 
 
 
(c)  
 
Figure 4.23 Results of TPFB with different conditions using oven for temperature and 
paper clips or weight for pressure (a) 104°C with two paper clips (67 psi) for 1 hour, (b) 
105°C with weight (8.8 psi) for over 1.5 hours, and (c) 105°C with weight (10.12 psi) for 
overnight (dark fields or arrows indicate bonded/collapsed area.) 
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 The pressure cooker was also used to the seal the HFRD1 devices. It gave better results 
with 2.5~3 psi operating pressure, with a resultant temperature of 104°C ~ 105°C, compared 
to the oven-based TPFB, but it still produced uneven sealing. Figure 4.24 shows a prototype 
HFRD1 sealed using the pressure cooker at 3 psi (=105°C) with DI-water. 
The third method was pressure sealing. The HFRD1 devices and cover sheet were 
sandwiched between two pieces of thick glass and pressed by paper clips. One side glass had 
holes for capillary connections. Figure 4.25 showes the pressure sealing demonstration and 
leakage experiments. 
Leakage tests of the HRFD1 prototypes were done using the pressure sealing method 
with food color. Results are shown in Figure 4.26. Pressure sealing method gave an 
acceptable seal. There was no leakage except at the highest flow rate (0.75 mL/min.)  
 
 
 
Figure 4.24 Sealed HRFD1 using pressure cooker 
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(a) (b) 
Figure 4.25 Sealing of the HFRD1 using (a) pressed sealing method and (b) leakage 
experiment with food color 
 
(a) 
 
 
(b) 
Figure 4.26 Leakage test of HFRD1: (a) Schematic drawing of HFRD1 and (b) leakage test 
with food color 
 
 
 
First Section Second Section 
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Target cell capture experiments with the HFRD1 devices were performed without 
antibody immobilization process. Target cells escaped through the 10 µm deep side channel 
and many target cells clogged the side channel. Figure 4.27 shows the clogged target cells in 
the side channel. The target cells escaped because of inappropriate cell conditions; fixed and 
stored in 70% ethanol over months, and the deep side channel. Even though the cell 
conditions were not appropriate, target cells should not escape freely.  So, the depth of the 
side channel needed to be reduced. 
 
 
 
Figure 4.27 Target cell capture using HFRD1: clogged target cells on the side channel after 
target cell escaping through the side channel (Red arrows indicate clogged target cells) 
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4.9.2 High Flow Rate Device Version Two (HFRD2) 
The HFRD2 was designed based on the simulation results and tested because the HFRD1 
had target cell loss and clogging of the side channel. The HFRD2, a combination of cases G4 
and S4 (Chapter 3.4.3), had a 5 µm deep side channel and a larger inlet cross-sectional area 
than HFRD1 to avoid target cell loss. The sealing of the HFRD2 was tried with TPFB and 
PMMA spin coating (PSC) method. TPFB sealing method used paper clips, local pressure 
control, or weight in a forced convection oven (VWR 1620, West Chester, PA, USA). Figure 
4.28 shows the local pressure control chip which has a symmetric design for HFRD2 to apply 
the pressure on the only contact area by pressing on the cover sheet. The applied conditions 
were 93~105°C and 5~20 psi. The results of the TPFB method were not acceptable and not 
consistent. The side channels were blocked by deformation during TPFB.  
The PMMA spin coating (PSC) method for the HFRD2 yielded good results. PMMA 
beads (molecular weight: 75000, polysciences, Inc., Warrington, PA) was dissolved in the 
PGMEA solution after three days mixing using a stirer. A mixing ratio of 2.5~5% (w/w) was 
used and the output filtered with a 0.2 µm membrane syringe filter. The 2.5% PMMA-
PGMEA solution was loaded on a PC sheet (4 inch diameter and 500 µm thickness) for spin 
coating.  
 
 
Figure 4.28 (a) Local pressure control chip for TPFB 
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Figure 4.29 (a) PSC_PC sealing method using a roller on a hotplate 
 
Three steps of spin coating angular velocity were used. The first step was 500 rpm for 5 
seconds, the second step was 4500 rpm for 60 seconds, and the last step was 1000 rpm for 60 
seconds. The PMMA spin coated PC (PSC_PC) sheet was put on a piece of glass for 5 
minutes at room temperature to dry and vaporize the solvent slowly and then placed on a 
55 °C hot plate. On the hot plate the HFRD2 and PSC_PC was sealed using a roller 
(Speedball, Art Products Co LLC, Statesville, NC, USA.) Figure 4.29 shows the PSC_PC 
sealing method using the roller. The thickness of the dried PMMA spin coated layer was less 
than 150 nm because the thickness of 5% PMMA-PGMES solution gave 150 nm with 75,000 
molecular weight PMMA after 4500 RPM spin coating and baking. 
A new capillary fitting method was introduced for easy and quick capillary connection. 
The inlet and outlets of the device were drilled using size #70 or #71 drill bits (Carbide drill, 
Kennametal Inc., Latrobe, PA USA) at 5000 rpm. The inlet and outlet ports could be tapered 
using a broken micro drilling bit. Pushing and rotating the broken drilling bit by hand in the 
inlets or outlets created tapered inlets or outlet ports. The capillary, 1/32 inch PEEK tube 
(IDEX Health & Science LLC, Oak Harbor, WA), could be directly connected with the 
HFRD 
PSC_PC 
Glass 
Hot Plate 
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tapered inlet and outlets without any other additional material such as, glue or epoxy. There 
was no leakage during the experiments because it was sealed by friction and fixed tightly 
between the capillary and tapered inlets or outlets. The maximum fitting pressure was not 
tested but it held enough pressure for any microdevice uses. Figure 4.30 shows the new 
capillary connection method and the PSC sealed and capillary connected HFRD2.  
The sealed HFRD2 devices were tested for the escape of target cells without antibody 
immobilization. Without antibodies the HFRD2 was only a size based target cell capture 
system. The target cells were in PBS and infused using a syringe pump. To test for the escape 
of target cells at each section and location, two of three outlets were closed using end closed 
10 µL pipette tips. The target cells could escape through the first section side channel at 25 
µL/min; 45 µL/min in the second section side channel also permitted the target cell escape. 
Figure 4.31 and Figure 4.32 show the target cells in the side channel or drain reservoir. 
 
(a) 
 
(b) 
Figure 4.30 Capillary connection method: (a) Tapered inlets and outlets could be made with a 
broken drill bit (inserted picture) and (b) direct capillary connection of HFRD2 without 
additional adhesive or bonding material 
Broken Drill Bit  
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(a) 
 
 
(b) 
Figure 4.31 Target cells that passed into the side channel; (a) Inlet flow rate was 25 µL/min 
and only one side outlet was opened (other outlets, right side outlet and main outlet, were 
closed.), (b) Target cells were found in the drain reservoir and on the side channel. 
 
 
 
 
 
 
Drain Reservoir 
Side Channel at the First Section 
Main Channel 
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(a) 
 
 
(b) 
Figure 4.32 HFRD2 target cell loss in the second section; (a) Inlet flow rate was 45 µL/min 
and only main outlet was opened (The first section outlets were closed.), (b) Remaining 
target cells in the side channel and in the main channel after rinse (target cells in the reservoir 
were washed out.) 
 
  
Side Channel at the Second Section 
Main Channel 
Drain Reservoir 
Supporting Post 
Target Cells 
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4.9.3 High Flow Rate Device Version Three (HFRD3) 
High flow rate device version three (HFRD3) was designed and fabricated based on the 
simulation results and experiments with the earlier prototypes. The inlet velocity could be 
reduced because the inlet cross-sectional area was increased. The inlet velocity of the 
HFRD1 was 278 mm/s, HFRD2 was 96 mm/s, and HFRD3 was 19 mm/s to match the target 
flow rate, 0.75 mL/min. The HFRD3 devices were sealed with thermoplastic fusion bonding 
(TPFB) and the PMMA spin coating method after UV modification. TPFB for the HFRD3 
was performed using paper clips, weights, the custom-made plunger spring assisted jig, and 
local pressure control method. Conditions for TPFB were 93~105 °C and 5~20 psi. The 
range of the temperature and pressure was narrowed down to 101~103 °C and 5~10 psi based 
on the TPFB results. However, the results of the TPFB were not consistent and local 
deformation was observed in most cases even through multiple tools and a variety of 
conditions were evaluated. Figure 4.33 shows the sealed HFRD3 after TPFB. The main 
channel or side channels were locally collapsed. The supporting posts in the main channel 
and in the side channels could not properly prevent the deformation for most cases.  
The reason for the local deformation was an uneven pressure distribution over the whole 
surface during TPFB. The main reason for the uneven pressure distribution was thickness 
variation of the hot embossed PMMA devices. The thickness variation of the hot embossed 
HFRD3 was 40 ~ 80 µm and compared to variation of pristine PMMA sheet (1/16 inch 
thickness) of 6 ~ 8 µm. More than three of the HFRD3 devices were investigated and the 
range of the thickness variations were 40 ~ 80 µm. The average thickness variation of the hot 
embossed HFRD3 devices is shown in Figure 4.35. The center area is 70 µm thicker than 
side area on the HFRD3. The thickness variation was caused by a nonuniform bottom press 
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plate in the Jenoptik HEX 02 (Jena, Germany) system at the Center for Advanced 
Microstructures and Devices (CAMD) at LSU. Because of this thickness variation, the TPFB 
of the HFRD3, which has 5 µm depth side channel, was not successful.  
 
Figure 4.33 HFRD3 after thermoplastic fusion bonding 
 
  
(a) Deformed and blocked main channel (b) Properly supported main channel 
  
(c) Blocked side channel (d) Well supported side channel 
Figure 4.34 Results of sealing using TPFB for HFRD3: (a) and (b) main channel area and (c) 
and (d) side channel area 
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Figure 4.35 Thickness variation of the hot embossed HFRD3 
 
 The PMMA spin coating (PSC) method was tried for sealing of the HFRD3 to overcome 
the thickness variation. The PSC sealed HFRD3 is shown in Figure 4.36. The depth of the 
side channel after sealing was examined under a microscope. It was roughly 5 µm but hard to 
define the exact number due to the rounded edge on the cross-sectional surfaces. After 
sealing, the HFRD3 was amine functionalized and antibody immobilized. 
Target cell capture experiments were accomplished after UV modification, amine 
functionalization, and antibody immobilization processes. Using a hemacytomer 100 live 
MCF-7 cells were prepared and spiked in PBS. The cells in PBS were drawn through the 
chips using syringe pumps. The flow rate for the target cell capture was 120 µL/min. The 
rinse was completed with PBS at 1200 µL/min after the capture of the target cells. The 
captured MCF-7 cells were fixed with -20 °C methanol, and then stained with DAPI. The 
captured MCF-7 cells were counted using a fluorescence microscope (Nikon Eclipse E600, 
Nikon Instruments Inc., Melville, NY). The average recovery rate of the MCF-7 cells in PBS 
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was 85%. In most cases, the target cells were captured at the side channel entrance area. 
Figure 4.37 shows the flow rate conditions and captured MCF-7 cells in the HFRD3.  
 
 
 
  
(a)  (b)  
  
(c)  (d)  
Figure 4.36 Sealing of HFRD3 using PMMA spin coated PC (a) Top view of side channel area 
without PMMA solution clogging, (b) Top view of side channel area with PMMA solution 
clogging, (c) Cross sectional view of side channel at the red line in (a), (d) Enlarged picture of 
red dotted rectangular in (c)  
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(a) 
  
  
(b) 
Figure 4.37 Target cell captured using HFRD3: (a) flow control at three outlets and (b) 
captured MCF-7 cells on the side channel entrance from PBS solution 
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Human red blood cell (RBC) tests were performed to confirm that the RBCs escaped 
through the side channel in the HFRD3. The RBCs were purchased from Innovative 
Research (Novi, Michigan USA.) The RBCs did tend to pass through the side channel. 
Figure 4.38 showed the RBCs flowing through the side channel. The red arrows indicate 
clumped RBCs in the side channel. Some of RBCs were locally clumped and partially 
blocked the side channel which causes pressure and velocity increase in the side channel. The 
RBC clumping may happen due to the coagulation or aggregation of the RBCs. Higher 
concentrations of RBCs and higher velocity gives more RBC clumps. Multiple 
concentrations (100%, 45%, 20%, 10%, and 5%) were tested and heparin (BD 8362834, 
Vacutainer with Sodium Heparin - 158 USP units, Franklin Lakes, NJ USA) was added. 
Higher concentration of the heparin and lower concentrations of RBCs gave better RBC flow 
in the side channel since it reduces the coagulation/aggregation and clumping of the RBCs. 
After the initial RBC flow tests, the HFRD3 was rinsed with PBS. Any RBCs remaining in 
the channels were fixed with -20 °C methanol and stained with DAPI which stains only 
nucleated cells. Some of the captured cells were stained with DAPI even though RBCs do not 
contain nuclei. DAPI stained individual cells were found at the side channel entrance region. 
The DAPI stained and clumped, coagulated, or lysed RBCs located in the side channel. The 
reason for the nuclear stain with RBCs is not clear. It may be due to under-developed RBCs 
or white blood cells which were not eliminated during the separation process. Figure 4.39 
show the stained cells (RBC or WBC) at the side channel entrance area and clumped RBCs 
in the side channels. Yellow arrows indicate individually stained cells at the side channel 
entrance and red arrows represent clumped RBCs in the side channel. The blue arrows show 
unstained and unknown cells. 
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(a) (b) 
Figure 4.38 RBCs flowing through 5 µm depth side channel: (a) flowing without RBC 
clogging or clumping and (b) lightly clumped RBCs in the side channel 
 
 
      
(a) (b) 
Figure 4.39 DAPI stained cells during RBC tests: (a) individual and heavily clumped RBCs 
and (b) individual and medium clumped RBCs 
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 Target cell capture from RBCs was accomplished. Target cells, MCF-7 cells, were 
harvested and stained with membrane fluorescence (PKH67, Sigma-Aldrich, St. Louis, MO) 
to overcome the RBC staining issue. The target cells were diluted until there were 20~30 
cells in 9 chambers (0.9 µL) in a hemacytometer and counted more than 5 times to minimize 
an error in the cell concentration. To collect 100 MCF-7 cells, the sample volume (3 µL ~ 4.5 
µL) was calculated and collected using a pipette. The collected cell solution was spiked into 
the RBCs. The RBC solutions containing target cells were delivered to the HFRD3 device 
using syringe pumps. After capturing the CTCs and washing with PBS, the captured CTCs 
were counted under a fluorescence microscope. Figure 4.40 shows the target cell capture 
experiment configuration. 
 
Figure 4.40 Target cell capture experiment configuration 
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The flow rates for the target cell capture was 150 µL/min and 750 µL/min and the 
concentration of the RBCs was 40~42%. Three experiments were done for each case. The 
target cells were in viable condition. For the case of 150 µL/min, the flow rate in the two side 
outlets (Wr and Wl) was 45 µL/min and the flow rate of the main outlet (Wo) was 60 µL/min. 
Figure 4.41 shows the flow rate control for the HFRD3. The sample mean target cell 
recovery rate was 81% with a sample standard deviation of 3.46 (Confidence Level (95.0%) 
= 3.92.) Table 4.6 shows the results of CTC capture from 100 viable MCF-7 cells at 150 
µL/min. Figure 4.42 shows the target cell recovery rate at 150 µL/min. Figure 4.43 shows the 
captured target cells in the HFRD3 device. Most of the target cells were captured near the 
entrance of the side channels at 150 µL/min. 
 
 
 
 
 Wr: Withdraw Flow Rate of the Right Side 
Channel Outlet 
 
 Wl: Withdraw Flow Rate of the Left Side 
Channel Outlet 
 
 Wo: Withdraw Flow Rate of the Main 
Outlet 
Figure 4.41 Flow rate control of the HFRD3 
 
Table 4.6 CTC capture from 100 viable MCF-7 cells at 150 µL/min 
Sample Number Captured CTCs Number 
1 79 
2 79 
3 85 
 
Wr 
Wl 
Wo 
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Figure 4.42 Target cell recovery rate with 100 viable MCF-7 cells at 150 µL/min (s.d.: 
sample standard deviation) 
 
  
  
  
Figure 4.43 Captured target cells at the side channel entrance area in HFRD3 from 100 viable 
MCF-7 cells at 150 µL/min 
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High flow rate target cell capture was accomplished with 100 or 13~16 viable MCF-7 
cells with 40~42 % RBCs at 750 µL/min (Wr = Wl = 200 µL/min and Wo = 350 µL/min.) 
The captured target cells were found not only at the side channel entrance area or in the main 
channel but in the side channel or in the drain reservoirs, which was not observed at 150 
µL/min. Figure 4.44 shows the target cells captured at the side channel entrance area, in the 
side channel, or in the drain reservoir in case of the 100 viable MCF-7 cells with 750 µL/min. 
The sample mean (mean) recovery rate was 76% and sample standard deviation (s.d.) was 
6.56 (Confidence Level (95.0%) = 7.42) except target cells trapped with RBCs in the drain 
reservoirs behind the side channels. The recovery rate was 85.67 ± 11.7% (mean ± s.d.) and 
confidence level (95.0%) = 13.3 if the trapped target cells in the drain reservoir were 
included. Table 4.7 shows the captured CTCs at each location. Figure 4.45 shows the 
recovery rates with 150 µL/min and 750 µL/min. 
 
 
   
Figure 4.44 Captured target cells in HFRD3 at 750 µL/min (a) at the side channel entrance and 
(b) in the side channel (blue arrow) and in the drain reservoir (red arrow) 
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Table 4.7 Location of captured MCF-7 cells from100 CTCs 
Q=750 µL/min (Wr=Wl=200 µL/min, Wo=350 µL/min), 100 Live MCF-7 Cells stained w/ PKH67 
100 CTCs 
Captured  
CTC Number 
1st Section 
Side Channel 
1st Section 
Main Channel 
2nd section 
Side 
Channel 
2nd Section  
Main 
Channel 
1st Section 
Reservoir 
2nd Section 
Reservoir 
HFRD3#310 
(42% RBCs) 
83 52 2 29 0 16 0 
HFRD3#306 
(40% RBCs) 
75 24 15 11 25 6 0 
HFRD3#303 
(40% RBCs) 
70 45 11 14 0 7 0 
 
 
 
 
Figure 4.45 Target cell recovery rate: 81 ± 3.46% (mean ± s.d.) for 150 µL/min, and 76 ± 
6.56% (mean ± s.d.) for 750 µL/min 
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Samples which were prepared statistically using a hemacytomter cannot provide the 
precise number of target cells. To overcome the uncertainty of the target cell numbers, exact 
numbers of target cells was used for target cell capture using single cell collection chip and 
capillary, shown in Chapter 4.6. The exact number of target cells was collected and spiked in 
the 40~42% RBC solution. The sample mean number (mean) and sample standard deviation 
(s.d.) of collected target cells was 14.67 ± 1.53 (mean ± s.d.) Different numbers of CTCs 
were collected due to slow response time of suction during target cell collection. The 
recovery rate was 84.94 ± 19.8% (mean ± s.d.) without trapped cells in the drain reservoir 
and 89.58 ± 18.0 (mean ± s.d.) with trapped cells in the drain reservoir.  Table 4.8 shows the 
captured CTCs at each location. Table 4.9 shows the percentage of captured target cells for 
each location (converted form Table 4.8.) Appendix D shows pictures of captured target cells 
for 10 CTC cases. 
Table 4.8 Number of captured target cells for each location in the high flow rate device3 
Q=750 µL/min (Wr=Wl=200 µL/min, Wo=350 µL/min), small number of  Live MCF-7 Cells stained w/ 
PKH67 
Small # of 
CTCs 
Used CTC 
Number 
1st Section 
Side Channel 
1st Section 
Main Channel 
2nd section 
Side Channel 
2nd Section  
Main Channel 
1st Section 
Reservoir 
2nd Section 
Reservoir 
HFRD3#322 
(40% RBCs) 
15 5 2 8 0 0 0 
HFRD3#312 
(40% RBCs) 
13 8 0 4 0 0 1 
HFRD3#315 
(42% RBCs) 
16 7 0 3 0 1 0 
 
Table 4.9 Percentage of captured target cells for each location (Converted from Table 4.8) 
Q=750 µL/min (Wr=Wl=200 µL/min, Wo=350 µL/min), small number of Live MCF-7 Cells stained w/ 
PKH67 
Percentage 
Used CTC 
Number 
1st Section 
Side Channel 
1st Section 
Main Channel 
2nd section 
Side Channel 
2nd Section  
Main Channel 
1st Section 
Reservoir 
2nd Section 
Reservoir 
HFRD3#322 
(40% RBCs) 
15 33.33 13.33 53.33 0.00 0.00 0.00 
HFRD3#312 
(40% RBCs) 
13 61.54 0.00 30.77 0.00 0.00 7.69 
HFRD3#315 
(42% RBCs) 
16 43.75 0.00 18.75 0.00 6.25 0.00 
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The recovery rate for 100 and 14.7 (mean number) cells at 750 µL/min with and without 
target cells in the drain reservoir is shown in Figure 4.46. The captured rate with each 
captured location with 750 µL/min is shown in Figure 4.47 and Figure 4.48 for 100 and 10 
MCF-7 cells. The p-value (Probability associated with a Student's paired t-Test, with a two-
tailed distribution) between 100 and 10 MCF-7 cells was 0.39 without the cell trapped in the 
drain reservoirs and 0.67 with cells trapped in the drain reservoirs. Figure 4.49 shows the 
frequency of captured target cell based on the locations. The p-values (100 and 10 MCF-7 
cells) for each location are also shown above the each pair of columns. The results show that 
50 ± 8.4% (mean ± s.d.) of the target cells were captured in the first section (main and side 
channel,) 30 ± 13.9% (mean ± s.d.) was captured in the second section (main and side 
channel,) 7 ± 5.1% (mean ± s.d.) was trapped in the drain reservoirs, and 12 ± 13.8% (mean 
± s.d.) were missed. 
 
 
Figure 4.46 Target cell capture (100 or 14.67 ± 1.53 (mean ± s.d.) MCF-7 cells in 40~42% 
RBC at 750 µL/min) using HFRD3 with and without trapped cells in the drain reservoirs. 
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Figure 4.47 Target cell capture (100 or 14.67 ± 1.53 (mean ± s.d.) MCF-7 cells in 40~42% 
RBC at 750 µL/min) using HFRD3 for each location without trapped cells in the drain 
reservoirs: Percentage of each location in the column indicates mean ± s.d.  (Probability: 
paired, two-tailed) 
 
40.33 ± 14.6% 
46.21 ± 14.3% 
9.33 ± 6.7% 
4.44 ± 7.7% 
18.00 ± 9.6% 
34.28 ± 17.6% 
8.33 ± 14.4% 
0
10
20
30
40
50
60
70
80
90
100 CTCs 14.7 CTCs
R
ec
o
v
er
y
 R
a
te
 (
%
) 
Number of Spiked CTCs 
2nd Section
Main Channel
2nd section
Side Channel
1st Section
Main Channel
1st Section
Side Channel
P = 0.39 
166 
 
 
 
Figure 4.48 Target cell capture (100 or 14.67 ± 1.53 (mean ± s.d.) MCF-7 cells in 40~42% 
RBC at 750 µL/min) using HFRD3 for each location with trapped cells in the drain reservoirs: 
Percentage of each location in the column indicates mean ± s.d. (Probability: paired, two-
tailed) 
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Figure 4.49 Frequency of captured target cells versus location for 100 and 14.67 ± 1.53  
(mean ± s.d.) MCF-7 cell cases. The flow rate was 750 µL/min and RBC concentration was 
40~42%. P-values between 100 and 14.67 ± 1.53 (mean ± s.d.) MCF-7 cell cases are above 
the columns for each location. (Probability: paired, two-tailed) 
 
 
 
  
40.33 
9.33 
18.00 
8.33 
46.21 
4.44 
34.28 
0
5
10
15
20
25
30
35
40
45
50
1st Section
Side Channel
1st Section
Main Channel
2nd section
Side Channel
2nd Section
Main Channel
C
a
p
tu
re
d
 C
T
C
s 
(%
) 
Capture Location 
100 CTCs
14.7 CTCs (%)
p = 0.76 
p = 0.61 
p = 0.11 
p = 0.42 
168 
 
 
4.10 Conclusions 
A high flow rate rare target cell capture device was successfully designed, fabricated, and 
captured CTCs with a high recovery rate. Multiple processes including device design and 
fabrication, surface functionalization, sample preparation, fluidic experiment, and target cell 
identification were carefully performed. A new sealing method was introduced to solve a 
sealing issue. New sample preparation method was established to overcome the limit of 
dilution method and applied to rare target cell capture experiment. The average recovery rate 
was 81% at 150 µL/min with 40 ~ 42 % RBCs from 100 viable MCF-7 cells. For 750 µL/min 
cases, the average recovery rate was 76% from 100 viable MCF-7 cells and 85% from small 
number of viable MCF-7 cells (13~16 cells.) Most of target cells (58% for 100 CTCs and 80% 
for 14.67 ± 1.53 (mean ± s.d.) CTCs) were captured at the side channels. At high flow rates 
(750 µL/min), exclusion of the target cells (< 14% for 100 CTCs and 10% for 14.67 ± 1.53 
(mean ± s.d.) CTCs) was observed in the drain reservoirs. The target cell capture with whole 
blood needs to be investigated and the optimum flow rate control at each outlet is required to 
increase the recovery rate. 
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CHAPTER 5: CONCLUSIONS AND FUTURE WORK 
 
 
5.1 Conclusions 
A new concept for a rare cell capture device at high flow rate was introduced to 
overcome the limitations of current methods. Current devices have some combination of low 
flow rate target cell capture, low recovery rate, low purity, or require pre-sample treatment. 
The performance of the high flow rate device (HFRD) was evaluated using computational 
fluid dynamics (CFD) simulations using Fluent v6.3 (ANSYS, Canonsburg, PA, USA). The 
working fluid was water, a Newtonian fluid, and assumed that the target cells would follow 
pathlines. These were used to identify the prospective device dimensions to optimize the 
performance of the device. Based on the CFD simulation results, prototype HFRDs were 
designed and fabricated in PMMA.  
For precise sample preparation, a new protocol for isolating single or small numbers of 
cells was introduced to solve the uncertainty inherent in the current method of preparing 
spiked blood samples which is based on statistical methods. Single cells or exact number of 
cells were successfully collected. The collected target cells were spiked in a red blood cell 
solution. The concentration of RBCs was 40~42% to match the hematocrit of normal human 
blood. Target cells were in a viable condition and stained with membrane fluorescence. 
Additionally, the target cells, the MCF-7 cell line, were successfully cultured and preserved. 
The HFRD prototypes were fabricated using hot embossing with micro milled brass mold 
inserts. The HFRDs were UV modified to produce carboxyl groups on the surface and amine 
functionalized. Antibodies were immobilized on the amine functionalized surface. 
Monoclonal anti-EpCAM was used for high specific capture of target cells. Sealing of the 
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HFRDs was completed using a spin coating technique. Since the aspect ratio of the HFRDs 
was very low (less than 0.01) at the side channels and the hot embossed HFRD was not flat, a 
new method was required instead of conventional thermoplastic fusion bonding. Thin PC 
sheets were used as substrates and PMMA solution (mixed with PMMA beads and solvent) 
was spin coated on the PC. The PMMA spin coated PC sheet could seal the HFRD. The 
thermoplastic fusion bonding was not successful because it requires flat surfaces. 
Circulating tumor cells, CTCs, were captured using antibody immobilized HFRD. The 
flow rate was 750 µL/min and recovery rate was 80.47 ± 12.85% (sample mean ± sample 
standard deviation) as a mean value of both cases for 100 and 14.67 ± 1.53 (sample mean ± 
sample standard deviation) cells. The target cells were cultured MCF-7 cells and 100 or a 
small numbers of viable cells (13~16 cells) were used.  
5.1.1 Simulation of High Flow Rate Devices 
 The goal of the design and the simulation was to find optimized dimensions to realize 
high flow rate (750 µL/min) with maximum target cell recovery in a micro device with a 
small footprint. Although the high flow rate device was designed and fabricated based on 
the simulation results, the simulation conditions were not those of the actual fluid, which was 
non-Newtonian with millions of solid blood cells in solution. Therefore, further simulations 
may give better performance. 
A new concept of the high flow rate cell capture design was verified by CFD simulation. 
The velocity vector was manipulated by adding side channels on the main channel. The 
lateral velocity vector was created and the pathlines or stream lines directed toward the side 
channel. The mean axial velocity was minimized to maximize the recovery rate. The lateral 
velocity along the contact path, the velocity at the point of target cell collision with the side 
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channel, was investigated to avoid target cell loss through the side channel. To optimize the 
HFRD design, 20 cases were simulated. Based on the simulation results, multiple designs 
were chosen and fabricated to test the performance. From the results, the original design was 
modified and simulated again. The final design was HFRD3. The first section has 40 mm 
long, 5~10 mm wide, and 130~30 µm deep main channel with 5 µm deep side channels. The 
second section has 33 mm long, 10 mm wide, and 30 µm deep main channel with 5 µm deep 
side channels. The end of second section was connected with drain reservoir without side 
channels to avoid clogging by leukocytes. 
 The inlet velocity was reduced to minimize the maximum velocities (axial and lateral 
velocities) by increasing the inlet cross-sectional area. The variable depth region of the main 
channel was designed to decrease the depth of the main channel to increase the encounter 
rate in the second section of the main channel. The length of the variable depth region was 40 
times larger than initial depth of the variable depth region of the main channel to avoid 
sudden velocity increase in that area. Since the depth of the side channel is 5 µm, red blood 
cells could be filtered out through side channels, while the target cells should not pass 
through.  
5.1.2 Rare Sample Preparation for CTC Capture 
Sample preparation has been an issue in CTC studies because methods of preparation of a 
single or precise number of CTCs in suspension has not been reported or was not suitable for 
CTC capture using a micro device. Therefore, a new protocol for collection of a single or 
precise number of cells was established. MCF-7 cells were successfully collected using a 
capillary tube with the polyimide removed and a cell collection chip. The target cells 
collected in the capillary were transported to the desired location, and spiked in blood. 
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5.1.3 Fabrication of a High Flow Rate Device 
 A high flow rate device was designed and fabricated based on the simulation results. 
Mold insert fabrication was completed using micro milling. The mold insert was successfully 
hot embossed in polymethyl methacrylate (PMMA.) The PMMA high flow rate device was 
UV modified for carboxyl group and amine functionalization and antibody immobilization 
process were followed. The HFRD3 was sealed using a spin coating technique. To achieve 
very low aspect ratio sealing, a new protocol of spin coating sealing method was established. 
5.1.4 Target Cell Capture Using High Floe Rate Device Three 
A statistically-prepared target cell sample, normally 100 MCF-7 cells, and an exact 
number of target cells, 14~16 MCF-7 cells using the new cell collection method, were used 
to capture the target cells using the final prototype. The target cells could be captured using 
the antibody immobilized surface in the device. A flow rate of 750 µL/min and mixture with 
~ 40% human red blood cells used. The recovery rate was 76 ± 6.56% (sample mean ± 
sample standard deviation) from the cell sample 100 and 84.94 ± 19.81% (sample mean ± 
sample standard deviation) from the small number of CTCs, 14.67 ± 1.53% (sample mean ± 
sample standard deviation) and confidence level with 95% = 1.73. 
5.2 Future Work 
The high flow rate target cell capture from human whole blood is a necessary step for 
further clinical applications in particular, point-of-care. The effect of leukocytes needs to be 
tested and may be minimized by modification of the plain cover sheet. Clinical tests with 
patient`s blood is the next step for the clinical use. 
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The recovery rate will be increased by manipulating the flow rate at each outlet and 
modification of the main outlet area. Moreover, a nano- or submicro-patterned cover sheet 
may increase the recovery rate and purity of the captured target cells. The footprint can be 
reduced by eliminating unnecessary area. Thermoplastic fusion bonding will be applied for 
HFRD sealing to expand the capture surface. 
To capture EpCAM negative CTCs, multiple antibodies can be immobilized on the 
capture zone. The prototype can also be used for detection of infection disease by inverting 
the function and placing capture zone in the side channel. Methicillin-resistant 
Staphylococcus aureus (MRSA) or Escherichia coli (E. Coli) can be captured with proper 
antibodies in the side channels.  
The HFRD3 can be used for a smart blood cell collection tube. The HFRD3 can be 
embedded in the tube and capture the target cells or viruses. The HFRD3 can be a portable 
capture device for cancer or infection disease. The HFRD3 can be combined with PCR or 
LDR micro device using a modular concept to eliminate false-positive results. 
Simulation of CTC collision/exclusion at the side channel can give very variable and 
critical information for the next generation of the HFRDs. The exclusion conditions (side 
channel depth, pressure gradient, and binding force) may give selective exclusion with proper 
channel dimensions and operating conditions.  
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APPENDIX A: CUSTOM MADE PLUNGER SPRING ASSISTED JIG AND 
LOCAL PRESSURE CONTROL METHOD 
 
A custom made plunger spring assisted jig (designed and fabricated by Dr. Daniel 
Sangwon Park in Louisiana State University) was used for thermoplastic fusion bonding. The 
jig was used to manipulate local pressure at each point of plunger. However, the pressure 
variation over the whole device may not be much different since the pressure of each plunger 
spring amy dispersed due to the thick glass on the outside of the high flow rate device. Figure 
A.1 and Figure A.2 show the jig and assembled condition with the device and the glasses. 
 
Figure A.1 Custom made plunger spring assisted jig for thermoplastic fusion bonding 
 
 
Figure A.2 Custom made plunger spring assisted jig assembled with high flow rate device 
and glasses 
Glasses 
 
High flow rate device with cover sheet 
 
Plunger spring  
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Local pressure control sheets were used to avoid channel deformation on the main and 
side channel. A Kapton tape (MSK00052, 1stmaskingtape, Torrance, CA, USA) was put on 
the high flow rate device and removed the channel area only. The channel area removed 
Kapton tape can control the local pressure. The substrate was the high flow rate device which 
has symmetric geometry. The local pressure control sheet was assembled with the high flow 
rate device and an alignment guide to give the pressure on only the Kapton tape area during 
thermoplastic fusion bonding process. Figure A3. And Figure A.4 show the local pressure 
control sheets, high flow rate device with Kapton tape, with and without alignment guide. 
 
Figure A.3 Local pressure control sheet 
 
 
Figure A.4 Local pressure control sheet with alignment guide 
  
Symmetric of high flow rate device 
Channel area removed kapton tape  
Channel area removed kapton tape  
 
Kapton tape removed channel area 
 
Guide for alignment 
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APPENDIX B: WATER CONTACT ANGLE DATA 
 
The water contact angle of hot embossed PMMA was measured to assess the effects of 
UV modification and IPA rinsing. Hot embossed PMMA showed 92° a water contact angle 
without UV treatment and it became more hydrophobic after UV modification. After an IPA 
rinse the UV modified PMMA water contact angle was decreased by about 20°. Figure B.1 
shows the water contact angle changes after UV modification and after the IPS rinse. Each 
value was an average number of left and right water contact angle, and it rearranged from the 
low to high in each column. 
 
 
Table B.1 Water contact angle of hot embossed PMMA before and after IPA rinse. 
Exposure 
time 
0 minutes 5 minutes 10 minutes 15 minutes 
Steps None UV After  
UV 
After  
Rinse 
After  
UV 
After  
Rinse 
After  
UV 
After  
Rinse 
M
ea
su
re
m
en
ts
 
87.50 81.50 69.50 83.50 60.50 86.00 71.50 
90.00 84.00 74.00 92.50 61.00 91.00 71.50 
90.50 86.50 74.50 93.00 63.50 95.50 72.00 
90.50 87.00 74.50 95.50 67.00 98.00 72.50 
91.50 88.00 74.50 97.00 69.00 98.50 74.00 
92.00 89.00 
 
97.50 70.00 99.50 74.00 
92.50 89.00 
 
98.00 70.50 99.50 74.50 
92.50 89.00 
 
99.00 73.00 99.50 74.50 
93.50 89.00 
 
100.5 73.50 100.00 75.00 
93.50 89.50 
 
101.00 74.00 100.50 75.00 
93.50 90.00 
 
101.50 74.00 100.50 75.00 
94.00 91.00 
  
75.00 101.00 75.50 
94.50 93.00 
  
78.00 101.00 
 
 
96.00 
  
79.50 102.00 
 
 
97.00 
   
102.00 
 
 
97.50 
   
102.50 
 
Average 92.00 89.81 73.40 96.27 70.61 98.56 73.75 
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Table B.1 Water contact angle of hot embossed PMMA before and after IPA rinse (continued) 
Exposure time 20 minutes 30 minutes 60 minutes 
Steps After UV After Rinse After UV After Rinse After Rinse 
M
ea
su
re
m
en
ts
 
90.50 68.00 77.50 67.00 73.50 
91.50 68.50 78.50 69.00 76.00 
91.50 69.00 78.50 69.00 76.00 
91.50 69.50 79.50 70.50 77.00 
93.50 71.00 80.00 71.50 77.00 
93.50 71.00 81.00 72.00 77.00 
94.00 71.50 81.50 72.50 78.50 
94.00 71.50 83.50 73.00 79.50 
94.50 72.50 84.50 73.50 79.50 
95.00 72.50 85.50 75.00 79.50 
95.50 
 
86.50 75.50 81.00 
96.50 
 
86.50 79.00 83.50 
96.50 
 
86.50 79.00 84.50 
99.00 
  
82.00 85.50 
99.00 
   
88.00 
101.50 
    
Average 94.84 70.50 82.27 73.46 79.73 
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APPENDIX C: CELL CULTURE, PRESERVATION, AND THAWING 
 
C.1 MCF-7 Cell Line Culture Process 
The MCF-7 cell line was cultured for the cell capture experiments. The complete growth 
medium for the MCF-7 cell line was a mixture of high glucose Dulbecco's Modified Eagle 
Medium (DMEM) from GIBCO (Carlsbad, California, USA) or Eagle's Minimum Essential 
Medium (EMEM) from ATCC (Manassas, VA, USA.) Heat-Inactivated Fetal Bovine Serum 
(FBS) from GIBCO (Carlsbad, California, USA), Penicillin-Streptomycin Solution (P/S) 
from ATCC (Manassas, VA, USA), and an insulin solution from bovine pancreas (B/I) from 
INVITROGEN (Carlsbad, California, USA.) The cell line was cultured in T-25 tissue culture 
flasks from BD Biosciences (Franklin Lakes, NJ, USA.) The basic cell culture products and 
companies are shown in the Table C.1. The conditions for the cell culture were 95% air and 5% 
carbon dioxide at 37 °C. The media were changed every 2 ~ 3 days and the MCF-7 cells 
were subcultured before they fully occupied the T-25 flask surface. The mixing ratio of the 
each solution was DMEM 450 ml, FBS 50 ml, P/S 5 ml, and B/I 500 μl. Figure C.1 shows 
the cultured MCF-7 cells in a T25 flask. The protocol for making the growth medium is 
explained in Table C.2. 
Table C.1 Cell culture products and companies 
Product Company 
Dulbecco's Modified Eagle Medium GIBCO (Carlsbad, California, USA) 
Eagle's Minimum Essential Medium ATCC (Manassas, VA, USA) 
Heat-Inactivated Fetal Bovine Serum GIBCO (Carlsbad, California, USA) 
Penicillin-Streptomycin Solution ATCC (Manassas, VA, USA) 
Insulin solution from bovine pancreas INVITROGEN (Carlsbad, California, USA) 
T-25 tissue culture flasks BD Biosciences (Franklin Lakes, NJ, USA) 
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(a) (b) 
Figure C.1 Culturing MCF-7 cells (p-159) (a) for one day and (b) for five days from 
subculture 
 
Table C.2 Protocol for making complete growth medium for MCF-7 cell line 
Step Process 
1 DMEM 450 ml (Remove 50 ml of DMEM from 500 ml bottle) 
2 Add 10% FBS (50 ml FBS) 
3 Add 100U P/S (5 ml Penicillin - Streptomycin) 
4 Add 0.01 mg/ml B/I (500 μl Bovine Insulin) 
5 Mix the solution well and aliquot the medium in 50 ml tubes 
6 Store the 50 ml tubes in 4 °C 
 
The first rule of the cell culture is to avoid contamination which changes the properties or 
morphology of the cells and eventually can kill the cells. Recovering and finding the 
contamination source should be carefully performed by sterilizing all cell culture supplies, 
including all surfaces of the bio safety cabinet and incubator using 70% ethyl alcohol. 
Pipettes and pipette tips need to be autoclaved. Moreover, the cell culture medium needs to 
be checked. Incubation of only the medium can confirm the presence contamination using a 
microscope. Figure C.2 shows the contaminated MCF-7 cells and contaminated medium. 
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(a) (b) 
Figure C.2 Contamination of the cells: (a) contaminated MCF-7 cells after 3 day 
subculture and (b) contaminated medium after 3 day incubation 
 
Subculture of the MCF-7 cell was done when the MCF-7 cells occupied 80 ~ 90% of the 
area in the T25 flask. Subculturing or passaging the attached cells required trypsinization. 
The trypsinization time was minimized to obtain healthy cells and to maximize cell viability. 
The protocol for the MCF-7 cell line subculture is shown in Table C.3. 
Table C.3 Protocol of MCF-7 cell line subculture 
Step Process 
1 Discard media and add PBS (3 ml) in a T25 flask for washing 
2 Discard the PBS and put 1 ml trypsin in the T25 flask 
3 Incubate in CO2 incubator about 10 min 
(Do not rock or shake the flask to avoid cell clumping) 4 Prepare 4 ml pre-warmed media in a new T25 flasks 
5 Confirm the cell detachment using a invert microscope 
6 Add 3 ml media in the flask and then transfer to 10 ml centrifuge 
tube 7 Centrifuge at 125 x g for 5 ~ 10 min at 20 °C 
8 Discard the supernatant solution (media and trypsin) and remain cell 
pellet 9 Add 1ml media and carefully pipette several times 
10 Put the cell suspension in the new flasks containing 4ml media 
 
 
183 
 
 
C.2 Cell Preservation and Thawing 
Preservation of the cultured cells was done using dry ice instead of an ultra low 
temperature deep freezer since the temperature of the dry ice is -78.5°C. The freezing media 
were 50% cell culture media, 40% FBS, and 10% Dimethylsulfoxide (DMSO, from ATCC, 
Manassas, VA, USA.) Alternatively, 90% FBS and 10% DMSO was also used as cell 
freezing media. The cell stock solution, cultured cells in cell freezing media, was transferred 
in 2 mL cryovial and then inserted in an IPA filled cell freezing container (Mr. Frosty from 
Sigma, St. Louis, MO, USA.) The cell freezing container was placed in an insulation box and 
fully filled with dry ice. The rate of temperature decrease in the IPA-filled cell freezing 
container was approximately -1°C /min which is the optimum condition for freezing common 
cells. The cell freezing process should be done quickly to maximize the cell viability because 
the Dimethylsulfoxide (DMSO) can damage the cells. The cells should be healthy and the 
cell culture media should be changed one day before cell freezing. During cell should be 
taken of contamination. Cell freezing using dry ice is shown in Figure 4.16. The temperature 
of the cells in dry ice was around -74°C. After 8 ~ 12 hours, the frozen cell stock in dry ice 
was stored in a liquid nitrogen tank. The cell stock information (cell type, passage number, 
cell freezing media, date, stock volume, and canister and cane number in liquid nitrogen tank) 
was well recorded.  
The frozen cell or cell stock was thawed to culture. Thawing the cells should be done as 
quickly as possible to minimize the cell damage from DMSO. Table C.4 shows the protocol 
for cell thawing. 
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(a) (b) 
Figure C.3 Cell freezing using dry ice: (a) cryovial in the cell freezing container and (b) 
insulation box with cell freezing container and dry ice  
 
 
 
Table C.4 Protocol of Cell Thawing 
Step Process 
1 Place the 50 ml cell growth medium in a 37 °C water bath over 30 minute. 
2 Prepare 10 ml media in a 15ml centrifuge tube and 4 ml media in a T25 flask. 
3 
Put a frozen cell stock into a 37 °C water bath for 1-2 minutes until it thawed. 
(Do not to totally immerse the stock sample - this may cause contamination) 
4 Transfer the cell stock into the centrifuge tube containing 10 ml media. 
5 Centrifuge at 125 x g (1000 rpm for 10 ml tube) for 5 min at 20 °C. 
6 Discard supernatant media and add 1 ml media in the tube. 
7 Slowly pipette the whole cell stock. 
8 Transfer the cell solution into the flask containing pre-warmed medium (4 ml for T25). 
9 Incubate in a CO2 incubator 
10 Change media on next day 
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APPENDIX D: TARGET CELL CAPTURE DATA 
 
Captured target cells in the high flow rate device3 (HFRD3) were counted at each 
location. Table D.1 shows the location of captured target cells. The prospective number of 
target cells (MCF-7) was 100 which were prepared using dilution method. The flow rate was 
750 µL/min and concentration of the RBC was 40~42% for all cases. 
 
Table D.1 Location of captured MCF-7 cells from100 cells 
Q=750 µL/min (Wr=Wl=200 µL/min, Wo=350 µL/min), 100 Live MCF-7 Cells stained w/ PKH67 
100 CTCs 
Collected 
CTCs 
1st Section 
Side 
Channel 
1st Section 
Main 
Channel 
2nd section 
Side 
Channel 
2nd Section  
Main 
Channel 
1st Section 
Reservoir 
2nd Section 
Reservoir 
HFRD3#310  
(42% RBCs) 
100 52 2 29 0 16 0 
HFRD3#306 
(40% RBCs) 
100 24 15 11 25 6 0 
HFRD3#303  
(40% RBCs) 
100 45 11 14 0 7 0 
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Table D.2 shows the location of captured target cells from small number of the MCF-7 
cells. Exact number of MCF-7 cells was spiked in RBC solution using cell collection chip 
and polyimide removed capillary. The flow rate was 750 µL/min and the concentration of the 
RBCs was 40~42% for all cases. 
 
 
Table D.2 Number of captured target cells for each location in the high flow rate device3 
Q=750 µL/min (Wr=Wl=200 µL/min, Wo=350 µL/min), small number of  Live MCF-7 Cells stained w/ 
PKH67 
Small # of 
CTCs 
CTC 
Number 
1st Section 
Side 
Channel 
1st Section 
Main 
Channel 
2nd section 
Side 
Channel 
2nd Section  
Main 
Channel 
1st Section 
Reservoir 
2nd Section 
Reservoir 
HFRD3#322  
(40% RBCs) 
15 5 2 8 0 0 0 
HFRD3#312 
(40% RBCs) 
13 8 0 4 0 0 1 
HFRD3#315  
(42% RBCs) 
16 7 0 3 0 1 0 
 
Table D.3 Percentage of captured target cells for each location (Converted from Table D.2 ) 
Q=750 µL/min (Wr=Wl=200 µL/min, Wo=350 µL/min), small number of Live MCF-7 Cells stained w/ 
PKH67 
Percentage 
CTC 
Number 
1st Section 
Side Channel 
1st Section 
Main Channel 
2nd section 
Side Channel 
2nd Section  
Main Channel 
1st Section 
Reservoir 
2nd Section 
Reservoir 
HFRD3#322 
(40% RBCs) 
15 33.33 13.33 53.33 0.00 0.00 0.00 
HFRD3#312 
(40% RBCs) 
13 61.54 0.00 30.77 0.00 0.00 7.69 
HFRD3#315 
(42% RBCs) 
16 43.75 0.00 18.75 0.00 6.25 0.00 
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Figure D.1 Captured MCF-7 cells from HFRD3#322: 15 of 15 cells in the channels 
 
 
 
 
Double cells 
 
Double cells 
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Figure D.2 Capture MCF-7 cells from HFRD3#312: 12 of 13 cell in the channel and 1 cells 
in the drain reservoir 
  
Trapped cell in 
the drain reservoir 
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Figure D.3 Capture MCF-7 cells from HFRD3#315: 10 of 16 cells in the channel and 1 cell 
in the drain reservoir 
  
Trapped cell in the 
drain reservoir 
Double cells 
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APPENDIX E: PROTOCOL FOR THERMOPLASTIC FUSION BONDING 
 
1. Preparation of the thermal bonding (flatting, dehydration, and cleaning) 
a. Check the flatness of the polymer device 
Light reflection on the device surface may a good simple way to check the flatness. 
b. Put the polymer device, cover slip, and glasses in 80°C oven for overnight for 
dehydration and annealing 
If the device was bended, use paper clips to press a sandwich assembled chip with two 
thick glasses (over 1 cm). 
c. Blow out any dust or particle on the device using nitrogen gas 
Blow at low pressure with over 10 cm distance from the device to avoid any liquid drop 
formation. 
2. Appling pressure and temperature for thermal bonding 
a. Assemble the polymer device with cover slip between thin pieces of glass 
Use gloves always, do not touch the bonding surface. 
b. Put the assembled polymer device, cover slip, and glasses in a 50°C pre-set oven 
c. Put a weight on top of the glass 
The pressure needs to be calculate based on the contact area and the weight 
d. Set the operating temperature at the desired point 
The operating temperature needs to be control based on the materials and the thermal 
bonding results. 
Recommending operating temperatures are 105°C for pristine PMMA, 101°C for UV 
modified PMMA, and 150°C for pristine PC. 
 The operating temperature and pressure need to be control as a combination. 
 The temperature increasing rate should be control not to be over the target 
temperature.  
e. Wait for two hours and set the temperature at 50°C  
f. Wait over 30 minutes until the temperature cools down to around 60°C and take 
away the thermal bonded device from the oven 
g. Separate the sandwich assembled device from the glasses 
The glass will be pot up from the polymer device if the warmed sandwich assembled 
glasses and device put on a cold metal surface 
3. Testing 
 Sealing test can be done by pushing air using syringe in water after capillary 
connection process 
To visualize the sealing performance, food color or fluorescence may be useful. 
 Deformation test can be done by looking the cross section of the channel under 
microscope 
Sandpaper and polymer polishing chemicals may help to clean the cross section  
 
191 
 
 
APPENDIX F: PROTOCOL OF AMINE FUNCTIONALIZATION 
 
1. Preparation of the amine functionalization solution 
Mix smoothly 0.659 g EDC + 1 ml Ethylenediamine + 100 ml PBS 
(Modified dilution: 3.25 g EDC + 5 ml Ethylenediamine + 500 ml PBS) 
2. Draw the amine functionalization solution into the channel by withdrawing  
3. Wait until the solution filled all the channel 
4. Shake the solution fully filled PMMA device for 60 minutes 
5. Do the step 2 ~4 again to confirm the amine functionalization 
6. Dry by nitrogen gas 
 
  
192 
 
 
VITA 
Taehyun Park was born in Mungyeong, Gyeongbuk, South Korea. After completing high 
school, he joined Kyungnam University, Masan, Gyeongnam, South Korea, where he earned 
his Bachelor of Engineering in Mechanical Engineering in 2001. He joined the Department 
of Mechanical Engineering at Louisiana State University in Spring 2003, where he began 
research in BioMEMS under the supervision of Dr. Michael C. Murphy. He is expected to 
earn the degree of Doctor of Philosophy on May 20, 2011. 
 
